[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 111
1. Zhang J, Jianmin, Wang N, Shi J, Ge X: A case of primary oncocytic adenocarcinoma of the lacrimal sac. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary oncocytic adenocarcinoma of the lacrimal sac.
  • Neoplasms of the lacrimal system may conveniently be grouped into epithelial and non-epithelial types: papillomas are the most common benign epithelial tumours, while oncocytic adenocarcinomas are extremely rare.
  • Here we report a case of primary oncocytic adenocarcinoma of the lacrimal sac in a 56-year-old man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orbit. 2005 Dec;24(4):291-3 [16354642.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):476-90 [7413136.001]
  • [Cites] Ear Nose Throat J. 1995 Oct;74(10):717-20 [8529551.001]
  • [Cites] Ophthalmic Surg. 1995 Jul-Aug;26(4):377-9 [8532297.001]
  • [Cites] Arch Ophthalmol. 1978 Feb;96(2):303-4 [629677.001]
  • (PMID = 21747898.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029480
  •  go-up   go-down


2. Al-Abed Y, Gray E, Wolfe K, Watters GW, Philpott JM: Metastatic Hurthle Cell Carcinoma of the thyroid presenting as a Breast Lump: A Case Report. Int Semin Surg Oncol; 2008;5:14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle Cell Carcinoma of the thyroid presenting as a Breast Lump: A Case Report.
  • BACKGROUND: Hurthle cell carcinoma of the thyroid is a rare form of thyroid cancer.
  • It may present as a low grade tumour or can present as a more aggressive metastatic carcinoma.
  • Hurthle cell carcinoma has the highest incidence of metastasis among all differentiated thyroid cancers.
  • We present the first case of breast metastasis from Hurthle cell carcinoma of the thyroid.
  • CASE PRESENTATION: We report a 77 year old lady who had total thyroidectomy and bilateral neck dissection followed by radiotherapy for a high grade metastatic Hurthle cell carcinoma of the thyroid.
  • Fine needle aspiration cytology of the lumps and histology after wide local excision of the breast lump confirmed metastatic Hurthle cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1991 Oct;48(2):112-6 [1921396.001]
  • [Cites] Int J Surg. 2006;4(4):204-5 [17462351.001]
  • [Cites] J Postgrad Med. 2005 Apr-Jun;51(2):125-7 [16006706.001]
  • [Cites] Onkologie. 2004 Oct;27(5):469-71 [15585977.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1293-300 [8960043.001]
  • [Cites] Breast. 2004 Apr;13(2):155-8 [15019699.001]
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] World J Surg Oncol. 2004;2:27 [15306032.001]
  • (PMID = 18505578.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409361
  •  go-up   go-down


3. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B: Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer; 2006 Apr 15;106(8):1669-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
  • BACKGROUND: Follicular carcinomas of the thyroid gland, including its oncocytic variant (so-called Hurthle cell carcinoma), are subdivided into the indolent encapsulated ("minimally invasive") and the clinically aggressive widely invasive tumors.
  • There are, however, cases of encapsulated follicular carcinoma that recur and metastasize.
  • Identifying these cases at the time of diagnosis is crucial for prognostic and therapeutic considerations.
  • Because to the authors' knowledge most studies do not focus exclusively on the encapsulated Hurthle cell carcinoma (EHC), the current study attempted to identify predictors of recurrence in EHC.
  • METHODS: A tumor was defined as EHC if it was encapsulated, macroscopically well defined with microscopic but no macroscopic evidence of vascular or capsular invasion, and composed of > 75% follicular oncocytic cells.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Neoplasm Recurrence, Local. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534796.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Pusiol T, Franceschetti I, Piscioli I, Beltrame MA, Polce M, Sassi C: Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma. Acta Otorhinolaryngol Ital; 2010 Apr;30(2):110-4
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma.
  • Oncocytic carcinoma of the parotid gland is a rare neoplasm.
  • To the best of our knowledge the simultaneous occurrence of oncocytic carcinoma and second malignancy in another site (outside the parotid gland) has not been reported.
  • An oncocytic carcinoma of the parotid gland is described in 56-year-old male with simultaneous breast cancer, emphasising the value of aspiration cytology and imaging procedures in the diagnosis of parotideal neoplasms.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Carcinoma / pathology. Carcinoma / radiography. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] Acta Otolaryngol. 2008 Oct;128(10):1152-8 [18607904.001]
  • [Cites] Ear Nose Throat J. 2003 Sep;82(9):699-701 [14569705.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1099-102 [14674089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Laryngol Otol. 1965 Dec;79(12):1064-72 [5858167.001]
  • [Cites] Br J Surg. 1971 Nov;58(11):851-3 [5124858.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):351-6 [3473871.001]
  • [Cites] Radiology. 1987 Oct;165(1):183-9 [3628768.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):420-2 [1935522.001]
  • [Cites] Otolaryngol Head Neck Surg. 1991 Dec;105(6):868-76 [1787978.001]
  • [Cites] Ann Pathol. 1991;11(5-6):359-62 [1804158.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):479-82 [1571115.001]
  • [Cites] Indian J Cancer. 1992 Dec;29(4):230-3 [1293011.001]
  • [Cites] Cytopathology. 1994 Apr;5(2):110-3 [8038421.001]
  • [Cites] Diagn Cytopathol. 1994 Dec;11(4):376-9 [7895576.001]
  • [Cites] Cytopathology. 1995 Feb;6(1):54-8 [7734704.001]
  • [Cites] Am J Otolaryngol. 1995 May-Jun;16(3):200-4 [7661319.001]
  • [Cites] Cancer. 1998 Jun 25;84(3):153-9 [9678729.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Mar;57(3):325-8 [10077205.001]
  • [Cites] AMA Arch Pathol. 1953 Apr;55(4):328-46 [13030050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6 [15668471.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] J Otolaryngol. 2006 Jun;35(3):189-92 [16929996.001]
  • [Cites] Onkologie. 2006 Sep;29(8-9):388-90 [16974117.001]
  • [Cites] Br J Plast Surg. 2003 Oct;56(7):637-43 [12969661.001]
  • (PMID = 20559483.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2882149
  • [Keywords] NOTNLM ; Fine-needle aspiration cytology / Male breast cancer / Malignant tumours / Oncocytic carcinoma / Parotid gland
  •  go-up   go-down


5. Munitiz V, Martinez-Barba E, Riquelme J, Rodriguez JM, Piñero A, Parrilla P: Elevated basal calcitonin levels in a patient with a hurthle-cell carcinoma of the thyroid and neuroendocrine differentiation: report of a case. Surg Today; 2005;35(5):404-6
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated basal calcitonin levels in a patient with a hurthle-cell carcinoma of the thyroid and neuroendocrine differentiation: report of a case.
  • A thyroid nodule with elevated plasma levels of calcitonin is usually suggestive of a medullary thyroid carcinoma (MTC); however, thyroid and extrathyroid conditions have been reported with elevated plasma calcitonin levels in the absence of MTC.
  • Interestingly, histopathological examination revealed a Hurthle-cell carcinoma with positive neuroendocrine (NE) markers such as calcitonin and synapthophysin, but not with chromogranin staining.
  • [MeSH-major] Adenoma, Oxyphilic / blood. Calcitonin / blood. Thyroid Neoplasms / blood. Thyroid Nodule / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864423.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


6. Motta MP, Athanazio DA, Motta A, Studart E, Athanazio PR: Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement. Int J Surg Pathol; 2008 Oct;16(4):447-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement.
  • A case of parietal cell (oncocytic) adenocarcinoma in a 62-year-old woman is reported.
  • In the present case, the unusual finding of parietal cell (oncocytic) adenocarcinoma and extensive nodal metastasis in a woman is reported.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Parietal Cells, Gastric / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387987.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Piana S, Asioli S, Foroni M: Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features. Virchows Arch; 2006 Feb;448(2):228-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features.
  • Rectal adenocarcinoma with diffuse oncocytic features is a very rare lesion, having been reported only once in the English literature.
  • We describe a case of oncocytic adenocarcinoma of the rectum, associated with a villous adenoma, arising on a 66-year-old man.
  • On histological examination, the adenocarcinoma was composed of neoplastic glands lined by a strongly eosinophilic, granular epithelium that deeply infiltrated the rectal wall.
  • Molecular alterations observed in oncocytic changes and their significance with regards to neoplastic transformation are briefly discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450120.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR: p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol; 2007 Dec;1(2):123-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) can pose diagnostic challenges in the head and neck often resembling benign and malignant oncocytic lesions.
  • Nineteen oncocytomas, 9 cases of oncocytosis, 9 oncocytic carcinomas and 16 head and neck metastatic RCC were studied.
  • Morphologic features evaluated were cytoplasmic character (clear versus oncocytic), Fuhrman nuclear grade, mitotic rate, growth pattern, presence of lumens/blood lakes and stromal characteristics.
  • Tumors were stained with antibodies to p63, renal cell carcinoma marker (RCCm), CD10, and vimentin.
  • Eight benign oncocytic tumors (29%) had clear cell features while 6 metastatic RCC (37%) had oncocytic features.
  • Median Fuhrman nuclear grade was 2 in oncocytoma and oncocytosis and 3 both oncocytic carcinoma and metastatic RCC.
  • Mitotic rates were only significantly different between benign oncocytic tumors and metastatic RCC.
  • Seven benign oncocytic tumors (25%) and 5 oncocytic carcinomas (56%) had RCC-like vascular stroma.
  • All primary salivary gland tumors were positive for p63, predominately in basal cell-type distribution.
  • While clinical history and morphology usually are adequate, demonstration of p63 staining can definitively exclude metastatic RCC from the differential diagnosis of similar appearing tumors in salivary glands, namely oncocytoma and oncocytic carcinoma, with 100% specificity and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):657-62 [12087334.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1097-9 [12871991.001]
  • [Cites] Lab Invest. 1970 Dec;23(6):567-80 [5530737.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Laryngoscope. 1973 Jun;83(6):898-905 [4711327.001]
  • [Cites] Laryngoscope. 1981 Apr;91(4):517-9 [6261053.001]
  • [Cites] South Med J. 1981 Sep;74(9):1050-2 [7280750.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):684-92 [3562340.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):862-7 [3402976.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):174-8 [2656583.001]
  • [Cites] Histopathology. 1990 May;16(5):487-93 [2361662.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):203-12 [9279976.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):225-8 [9682986.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Head Neck. 2005 Aug;27(8):696-702 [16021638.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):676-85 [12033955.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • (PMID = 20614263.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2807526
  • [Keywords] NOTNLM ; Metastatic renal cell carcinoma / Oncocytic carcinoma / Oncocytoma / p63
  •  go-up   go-down


9. Yaqub A: Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature. W V Med J; 2009 Jul-Aug;105(4):23-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature.
  • OBJECTIVE: To describe case reports of a brother and sister pair with Hurthle cell carcinoma of thyroid.
  • Both had the disease diagnosed in later years of life, had cold nodules for 4-5 years before histological diagnosis, and both had local recurrence following thyroidectomy and postoperative radioiodine ablation.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Thyroid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585901.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


10. Lallu S, Naran S, Bethwaite P: Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases. Diagn Cytopathol; 2007 Jul;35(7):439-43
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases.
  • We discuss two cases of unsuspected metastatic thyroid carcinoma of Hurthle cell type, presenting as subcutaneous masses in the occipital scalp and supra-acetabular region of the right ilium; clinically suspected to be a lipoma and a vascular tumour, respectively.
  • In case 1, a definitive diagnosis of metastatic Hurthle cell carcinoma was made based on cell block preparation and positive immunohistochemical stains for thyroglobulin and thyroid transcription factor-1.
  • Case 2 was reported as suggesting an oncocytic process, metastatic Hurthle cell lesion.
  • These cases are of interest as the bland cytologic features may lead to an erroneous benign diagnosis.
  • Immunohistochemistry aids the definitive diagnosis of metastatic Hurthle cell carcinoma of thyroid especially when the presence of a previous thyroid lesion is not communicated to the laboratory.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Biopsy, Fine-Needle. Bone Neoplasms / secondary. Skin Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580356.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Al-Khatib K, Sieunarine K, Lindsay I, Smith JR: Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):429-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report.
  • Hurthle cell carcinoma, a variant of follicular carcinoma of the thyroid, has been regarded as an aggressive type of differentiated thyroid cancer.
  • It is diagnosed histologically and regarded as a carcinoma by the presence of vascular invasion or capsular invasion.
  • In this case report, a patient with a history of thyroid Hurthle cell carcinoma presented with what seemingly appeared to be a pelvic mass of gynecological origin, with a raised risk-of-malignancy index of 567.
  • They were diagnosed to be secondary lesions of Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma of the thyroid has not been known to be associated with the elevation of CA125 nor has it been known to metastasize to the small bowel and sigmoid colon.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Laparotomy / methods. Lymph Nodes / pathology. Ovariectomy / methods. Postmenopause. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445671.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Caloglu M, Yurut-Caloglu V, Altaner S, Huseyinova G, Unlu E, Karagol H, Uzal C: Oncocytic carcinoma of the parotid gland. Onkologie; 2006 Sep;29(8-9):388-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the parotid gland.
  • BACKGROUND: Oncocytic carcinoma is a rare tumor of major salivary glands.
  • Histochemical or electron microscopic confirmation of the oncocytic nature of the tumor cell is needed for differential diagnosis.
  • Malignant oncocytomas have the potential risk of developing distant metastases and demand long term follow-up after therapy.
  • CASE REPORT: A 58-year old man presented with a recurrent mass in the left parotid gland with a prior diagnosis of monomorphic adenoma in the same localization which had been treated by tumor excision in July 2002.
  • CONCLUSION: For an accurate approach in the management of patients, oncocytic adenocarcinoma should be considered in the differential diagnosis of lesions of the parotid gland, most of which are benign.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Parotid Neoplasms / pathology. Parotid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974117.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Yuen HK, Cheuk W, Cheng AC, Anh C, Chan N: Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):70-2
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora.
  • Incisional biopsy revealed malignant oncocytoma of the lacrimal sac.
  • Patients with malignant oncocytoma may present with simple epiphora in absence of other signs and symptoms such as blood stained tearing or purulent rhinorrhea.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237701.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Batistatou A, Doukas M, Baltogiannis G, Panelos J, Kamina S, Charalabopoulos K, Agnantis NJ: Early gastric carcinoma with oncocytic features and extensive metastases. Pathol Res Pract; 2007;203(7):539-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gastric carcinoma with oncocytic features and extensive metastases.
  • We present the case of a 63-year-old Caucasian woman with early gastric adenocarcinoma, suffering from extensive metastases at the time of initial presentation.
  • Microscopic examination of the gastrectomy specimen revealed an invasive adenocarcinoma with oncocytic features.
  • Interestingly, despite the fact that the carcinoma was pT1, it also was found to be N2, stage IV.
  • The biologic behavior of oncocytic adenocarcinoma of the stomach is still unclear.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590281.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. McGinnis M: Metastatic Hurthle cell carcinoma and medical certification. Aviat Space Environ Med; 2007 Nov;78(11):1078-9
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle cell carcinoma and medical certification.
  • Thyroid carcinoma is the most common malignancy of the endocrine system.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Work Capacity Evaluation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018444.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


16. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA: Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes; 2007 Nov;115(10):694-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenoma, Oxyphilic / radiography. Adrenal Gland Neoplasms / radiography. Carcinoma / radiography. Positron-Emission Tomography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058606.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Lombardi D, Piccioni M, Farina D, Morassi ML, Nicolai P: Oncocytic carcinoma of the maxillary sinus: a rare neoplasm. Eur Arch Otorhinolaryngol; 2006 Jun;263(6):528-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the maxillary sinus: a rare neoplasm.
  • Oncocytic neoplasms are tumors composed of oncocytes (i.e., epithelial cells with a large cytoplasm that is rich in mitochondria).
  • Occurrence of oncocytic carcinoma (or malignant oncocytoma) within the sinonasal tract is an unusual event.
  • We report a rare case of maxillary sinus oncocytic carcinoma occurring in a 45-year-old male.
  • Definitive histology was consistent with oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Maxillary Sinus Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474973.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Colella G, Apicella A, Bove P, Rossiello L, Trodella M, Rossiello R: Oncocytic carcinoma of the accessory lobe of the parotid gland. J Craniofac Surg; 2010 Nov;21(6):1987-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the accessory lobe of the parotid gland.
  • Oncocytic carcinoma is a rare tumor of the parotid gland.
  • The clinical and histologic difficulties in relationship to the diagnosis of a midcheek mass consisting of an unusual tumor are emphasized.
  • [MeSH-major] Adenocarcinoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cheek / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Masseter Muscle / pathology. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119478.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Katz-Selbst ML, Chhieng DC: Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland. Diagn Cytopathol; 2009 Nov;37(11):849-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland.
  • His past history was significant for resection of primary oncoctyic carcinoma of the right parotid gland 5 years ago.
  • Fine-needle aspiration biopsy of the right cheek mass was performed and demonstrated oncocytic cells without significant cytologic atypia.
  • On the basis of the past history and comparison of the histology of previously resected specimen, the cytologic impression was consistent with recurrent oncocytic carcinoma of the salivary gland.
  • The cytologic differential diagnosis should include other primary salivary gland neoplasms and metastatic disease.
  • [MeSH-major] Carcinoma / pathology. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526569.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Rouzbahman M, Serra S, Chetty R: Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy. J Clin Pathol; 2006 Oct;59(10):1039-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.
  • BACKGROUND: The introduction of preoperative chemoradiation into the treatment protocol of rectal adenocarcinomas has affected the microscopical morphology in subsequent resection specimens.
  • AIM: To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery.
  • Oncocytic change in this particular clinical context occurs as a reflection of cytotoxic damage or cellular hypoxia induced by chemoradiation resulting in degeneration of the cell and the oncocytic phenotype.
  • Oncocytic change may be an under-recognised histopathological change in rectal cancers receiving preoperative chemoradiation.
  • [MeSH-major] Adenocarcinoma / ultrastructure. Oxyphil Cells / ultrastructure. Rectal Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2000 Nov-Dec;24(6):417-22 [11206339.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):126-34 [10452578.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1108-20 [10504363.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Ultrastruct Pathol. 2003 Mar-Apr;27(2):87-94 [12746199.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):579-82 [12955503.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):215-23 [15043311.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Cancer. 1977 Sep;40(3):1330-6 [198093.001]
  • [Cites] Can J Surg. 1982 May;25(3):332-3 [6282429.001]
  • [Cites] Arkh Patol. 1986;48(6):79-81 [3019283.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Int J Gynecol Pathol. 1994 Oct;13(4):290-301 [7814190.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):206-8 [8617466.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):314-6 [8806968.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):181-3 [8917721.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • (PMID = 16467161.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1861763
  •  go-up   go-down


21. Abe T, Murakami A, Nakajima N, Inoue T, Ohde S, Miwa M, Ueda Y, Kawabata K, Watanabe K: Oncocytic carcinoma of the nasal cavity with widespread lymph node metastases. Auris Nasus Larynx; 2007 Sep;34(3):393-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the nasal cavity with widespread lymph node metastases.
  • The first case of oncocytic carcinoma which arose from the inferior turbinate of the nasal cavity with orbital invasion through the nasolacrimal canal and widespread lymph node metastases in the neck and face is reported here.
  • We think the oncocytic carcinoma of the nasal cavity may be a high-grade malignancy tumor.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Lymph Nodes / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology. Turbinates / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Disease Progression. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Microscopy, Electron. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Orbit / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459629.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Hu YW, Lin CZ, Li WY, Chang CP, Wang LW: Locally advanced oncocytic carcinoma of the nasal cavity treated with surgery and intensity-modulated radiotherapy. J Chin Med Assoc; 2010 Mar;73(3):166-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced oncocytic carcinoma of the nasal cavity treated with surgery and intensity-modulated radiotherapy.
  • Oncocytic carcinomas of the nasal cavity are extremely rare.
  • An 80-year-old man with a history of nasal oncocytoma had received excision twice previously.
  • Pathological examination revealed oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / therapy. Nasal Cavity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20231003.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


23. Giordano G, Gabrielli M, Gnetti L, Ferri T: Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features. World J Surg Oncol; 2006;4:54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features.
  • BACKGROUND: Oncocytic carcinoma is an extremely rare neoplasm of the salivary glands.
  • We report a case of oncocytic carcinoma arising in a parotid gland in a 66-year-old female.
  • RESULTS: Frozen sections revealed an infiltrative growth pattern and the diagnosis of a malignant epithelial lesion was made.
  • Thus, the final diagnosis was that of oncocytic carcinoma of parotid gland.
  • CONCLUSION: This neoplasm shows clinical, microscopical, histological and ultrastructural features of oncocytic carcinoma and this must be considered in the differential diagnosis of other proliferations in the parotid gland with abundant granular cytoplasm and metastatic oncocytic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Jan 1;59(1):107-12 [3539304.001]
  • [Cites] J Urol. 1985 May;133(5):762-6 [3886935.001]
  • [Cites] Histopathology. 1997 Nov;31(5):408-11 [9416480.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):199-203 [12509976.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):889-95 [3276393.001]
  • [Cites] Auris Nasus Larynx. 2005 Sep;32(3):305-8 [15869853.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] HNO. 2001 Feb;49(2):109-17 [11270192.001]
  • (PMID = 16923179.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1564019
  •  go-up   go-down


24. Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M: Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol Ital; 2009 Dec;29(6):305-11
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell tumours of the thyroid. Personal experience and review of the literature.
  • Hurthle cell carcinoma represents about 5% of differentiated thyroid carcinomas.
  • The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma.
  • Aim of the present study was to evaluate previously reported data and personal experience on the clinical and pathological features of patients affected by Hurthle cell tumour that may predict disease progression and death.
  • From 1992 to 2003, the Authors identified 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma.
  • Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients.
  • At histology, 9 adenomas, 5 "minimally invasive" and 14 invasive carcinomas were found.
  • Post-operatively, in Hurthle cell carcinoma patients, TNM staging showed 9 patients with stage I, 5 stage II, 4 stage III and one stage IVa (UICC, 2002).
  • All invasive carcinomas underwent (131)I therapy (91-585 mCi).
  • One Hurthle cell carcinoma patient received external beam radiotherapy.
  • Only one Hurthle cell carcinoma patient showed distant lung metastases at 60 months' follow-up.
  • In conclusion, Hurthle cell carcinoma was not found to present a more aggressive behaviour than follicular carcinoma, when risk factors, including extent of tumour invasion, were taken into account.
  • None of the patients with Hurthle cell adenoma showed a relapse or death caused by the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Aug;24(8):898-906 [10865033.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2616-25 [11352953.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):243-9 [11408821.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):911-7 [11420462.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1160-3 [11571953.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):331-5 [12057113.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2178-80 [12461336.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):207-10 [12578450.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Endocr J. 2004 Jun;51(3):265-77 [15256771.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):307-12 [15468114.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(3):165-8 [15493577.001]
  • [Cites] Surg Gynecol Obstet. 1974 Oct;139(4):555-60 [4479589.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):851-5 [6503367.001]
  • [Cites] Surg Gynecol Obstet. 1985 May;160(5):409-13 [3992444.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Oct;61(4):773-8 [2993348.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1613-7 [3948132.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):101-22 [3843689.001]
  • [Cites] Arch Surg. 1988 Jul;123(7):849-54 [3382350.001]
  • [Cites] World J Surg. 1988 Aug;12(4):488-95 [3048000.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Mayo Clin Proc. 1991 Jan;66(1):11-22 [1988751.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):305-15 [1636432.001]
  • [Cites] Surg Clin North Am. 1995 Jun;75(3):395-403 [7747248.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2946-53 [7559879.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801 [8608779.001]
  • [Cites] Surgery. 1996 Dec;120(6):1000-4; discussion 1004-5 [8957486.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):893-910 [9735140.001]
  • [Cites] Surgery. 1998 Dec;124(6):967-74 [9854570.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):329-37 [15536332.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2842-6 [18665423.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):230-4 [18722077.001]
  • [Cites] Otolaryngol Head Neck Surg. 2009 May;140(5):715-9 [19393417.001]
  • [Cites] Diagn Cytopathol. 2009 Aug;37(8):600-6 [19526577.001]
  • (PMID = 20463834.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] Thyroid cancer, Hurthle cell
  • [Other-IDs] NLM/ PMC2868205
  • [Keywords] NOTNLM ; Hurthle cell adenoma / Hurthle cell carcinoma / Thyroid
  •  go-up   go-down


25. Mizutari K, Naganishi H, Tanaka Y: Oncocytic carcinoma in the submandibular gland: report of a case based on anti-mitochondrial immunohistochemical observations. Auris Nasus Larynx; 2005 Sep;32(3):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma in the submandibular gland: report of a case based on anti-mitochondrial immunohistochemical observations.
  • Oncocytic carcinoma arising in the submandibular gland is a very rare tumor that has only previously been reported in nine cases.
  • This paper describes an additional case of oncocytic carcinoma in the right submandibular gland.
  • Consequently, we diagnosed the mass as oncocytic carcinoma.
  • Usually, electron microscopy is necessary to diagnose oncocytic lesions, but the paraffin-embedded tissue was not suitable for electron microscopy.
  • Immunohistochemistry using an anti-mitochondrial antibody was found to be useful and helpful for the diagnosis of oncocytic lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Immunohistochemistry / methods. Mitochondria / immunology. Submandibular Gland Neoplasms / diagnosis. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Antibodies. Cell Nucleus / pathology. Cytoplasm / pathology. Humans. Magnetic Resonance Imaging. Male. Microscopy, Electron. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869853.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies
  •  go-up   go-down


26. Lee JS, Choi JH, Oh YH: Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases. South Med J; 2009 Jun;102(6):659-62
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases.
  • Oncocytic carcinoma of the head and neck is a very rare neoplasm.
  • Only 11 cases of oncocytic carcinoma of the submandibular gland have been reported, and no cases have shown distant bone metastasis.
  • The submandibular gland and bone marrow biopsies were consistent with oncocytic carcinoma.
  • Our case is the first report of oncocytic carcinoma of the submandibular gland with disseminated bone metastases.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Bone Neoplasms / secondary. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Metastasis / pathology. Oxyphil Cells / pathology. Submandibular Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434038.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sugiyama T, Nakagawa T, Narita M, Nakamura S, Inui M, Tagawa T: Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies. Oral Dis; 2006 May;12(3):324-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies.
  • PURPOSE: In this study we evaluated pedunculated oncocytic carcinoma (OC) in the buccal mucosa via immunohistochemical and ultrastructural studies.
  • An incision biopsy revealed the diagnosis of oncocytic tumor, and enucleation was performed.
  • RESULTS: Histopathology results revealed that the tumor consisted of oncocytic cells, characterized by eosinophilic and granular cytoplasm, and atypical nuclei.
  • Electron microscopy revealed numerous dilated cytoplasmic mitochondria, and the cell contours and nucleic shapes of tumor cells were often irregular.
  • CONCLUSIONS: Because the histopathologic features of OC are similar to those of benign oncocytoma, the diagnosis of OC must be confirmed by a combination of clinical and ultrastructural characteristics.
  • [MeSH-major] Adenocarcinoma / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700744.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


28. ul Haq RN, Khan BA, Chaudhry IA: Prevalence of malignancy in goitre--a review of 718 thyroidectomies. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):134-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prevalence of papillary and follicular carcinoma was 33.33% each.
  • Anaplastic carcinoma was found in 23.81% of patients followed by Hurthle cell carcinoma in 9.53% of patients.
  • Prevalence of follicular carcinoma and anaplastic carcinoma is relatively higher in our country due to high incidence of iodine deficiency goitre.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Child. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Prospective Studies. Thyroidectomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067046.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


29. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, Nam SJ: Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci; 2005 Oct;20(5):853-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
  • To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas.
  • The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions.
  • Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas.
  • TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinoma (HC) and 42% of the PDC, while there was only focal staining in one case of the UC.
  • These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1166-71 [10534163.001]
  • [Cites] Mod Pathol. 2000 May;13(5):570-6 [10824930.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):42-8 [10937048.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):319-22 [14974863.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4987-93 [8402689.001]
  • [Cites] Endocrinology. 1995 Jul;136(7):3113-9 [7789339.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2168-72 [7608273.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4672-80 [7664688.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):251-61 [8822209.001]
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):32-8 [8985087.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2501-7 [9192832.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] J Pathol. 1998 Jul;185(3):267-72 [9771480.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):98-104 [15716612.001]
  • (PMID = 16224162.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / HBME-1 antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2779285
  •  go-up   go-down


30. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol; 2006 May;34(5):330-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
  • The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate.
  • The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change.
  • Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial.
  • A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue.
  • Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN.
  • Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).
  • The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.
  • There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771).
  • When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259).
  • Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077).
  • Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN.
  • Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis. Thyroid Nodule / pathology. Thyroid Nodule / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL: Variables predicting distant metastases in thyroid cancer. Laryngoscope; 2005 Apr;115(4):661-7
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic type was Hurthle cell carcinoma in 3, follicular in 3, papillary in 19, and 5 patients had focal anaplasia either in the primary site or regional metastases.
  • The median time to diagnosis of distant metastases was 3 months.
  • [MeSH-major] Carcinoma / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / secondary. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Age Factors. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Female. Follow-Up Studies. Forecasting. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Rate. Thyroglobulin / analysis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805877.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


32. Slough CM, Randolph GW: Workup of well-differentiated thyroid carcinoma. Cancer Control; 2006 Apr;13(2):99-105
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Workup of well-differentiated thyroid carcinoma.
  • BACKGROUND: Well-differentiated thyroid carcinoma (WDTC) includes three main entities: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and Hurthle cell carcinoma (HCC).
  • A thorough knowledge of the natural history and presentation of these carcinomas is vital to the thyroid surgeon.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Cell Differentiation. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Preoperative Care. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735983.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 72
  •  go-up   go-down


33. Bernardini FP, Orcioni GF, Croxatto JO: Oncocytic carcinoma of the lacrimal gland in a patient with neurofibromatosis. Ophthal Plast Reconstr Surg; 2010 Nov-Dec;26(6):486-8
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the lacrimal gland in a patient with neurofibromatosis.
  • Oncocytic carcinoma (OCA) is rare, and although its occurrence in the lacrimal gland has been documented, clinical and histologic data are lacking.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Neurofibromatoses / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700068.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Well established examples of this group include pleomorphic adenoma, adenomyoepithelioma, and adenoid cystic carcinoma.
  • Key examples include mucoepidermoid carcinoma and acinic cell carcinoma.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A, Al Nuaim A: High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Ann Saudi Med; 2008 Jul-Aug;28(4):277-81
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary thyroid cancer was found in 76%, the follicular variant in 14%, other variants (tall cell and sclerosing types) in 2%, Hurthle cell carcinoma in 4%, and pure follicular thyroid cancer in 4%.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596397.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


36. Guclu E, Oghan F, Ozturk O, Alper M, Egeli E: A rare malignancy of the parotid gland: oncocytic carcinoma. Eur Arch Otorhinolaryngol; 2005 Jul;262(7):567-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare malignancy of the parotid gland: oncocytic carcinoma.
  • Oncocytic carcinomas are uncommon; they represent 11% of all oncocytic salivary gland neoplasms, 0.5% of all epithelial salivary gland malignancies and 0.18% of all epithelial salivary gland tumors.
  • As oncocytes and atypical cells were seen at the cytologic examination of a fine-needle aspiration biopsy, this finding suggested a malignant epithelial tumor.
  • The result of the pathologic examination was oncocytic carcinoma regarding histopathologic and immunohistochemical findings and especially the invasive growth pattern.
  • The prognosis of oncocytic carcinomas is not well known because of their low incidence.
  • Further investigation of the prognosis of patients with oncocytic carcinoma of the parotid gland is warranted as more cases are reported.
  • [MeSH-major] Carcinoma / pathology. Oxyphil Cells / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592856.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Park HJ, Jang KT, Heo JS, Choi YL, Han J, Kim SH: A potential case of intraductal tubulopapillary neoplasms of the bile duct. Pathol Int; 2010 Sep;60(9):630-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lung tumor was an adenocarcinoma, and the bile duct tumor showed poorly differentiated carcinoma with eosinophilic cytoplasm.
  • Lung lobectomy and hemihepatectomy were performed under the impression of double primary neoplasms of the lung adenocarcinoma and oncocytic variant of the biliary papillary tumor.
  • Eosinophilic cytoplasm of the bile duct tumor was not oncocytic cytoplasm but pyknotic change due to necrosis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712650.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


38. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer; 2008 Jul 1;113(1):48-56
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
  • BACKGROUND: Radioactive iodine-refractory (RAIR) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinomas (TC) and are therefore the main focus of novel target therapies.
  • However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date.
  • Poorly differentiated thyroid carcinomas (PDTC) were defined on the basis of high mitotic activity (> or =5 mitoses/10 high-power fields) and/or tumor necrosis.
  • Other types of carcinomas were defined by conventional criteria.
  • Histologic characterization of the metastasis/recurrence in 70 patients revealed that 47.1% (n = 33 patients) had PDTC, 20% (n = 14 patients) had the tall cell variant (TCV) of papillary thyroid carcinoma, 22.9% (n = 16 patients) had well-differentiated papillary thyroid carcinoma (WDPTC), 8.6% (n = 6 patients) had Hurthle cell carcinoma (HCC), and 1.4% (n = 1 patient) had anaplastic carcinomas.
  • Approximately 68% of the PDTC primary tumors were initially classified by the primary pathologist as better-differentiated tumors on the basis of the presence of papillary and/or follicular architecture or the presence of typical PTC nuclear features.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18484584.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Arcinas A, Yen TY, Kebebew E, Macher BA: Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res; 2009 Aug;8(8):3958-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns.
  • Cell surface proteins have been shown to be effective therapeutic targets.
  • Thus, identification of cell surface and secreted proteins has been a prime area of interest in the proteomics field.
  • Most cell surface and secreted proteins are known to be glycosylated, and therefore, a proteomics strategy targeting these proteins was applied to obtain proteomic profiles from various thyroid cancer cell lines that represent the range of thyroid cancers of follicular cell origin.
  • In this study, we oxidized the carbohydrates of secreted proteins and those on the cell surface with periodate and isolated them via covalent coupling to hydrazide resin.
  • Thyroid cancer cell lines derived from papillary thyroid cancer (TPC-1), follicular thyroid cancer (FTC-133), Hurthle cell carcinoma (XTC-1), and anaplastic thyroid cancer (ARO and DRO-1) were evaluated.
  • An average of 150 glycoproteins were identified per cell line, of which more than 57% are known cell surface or secreted glycoproteins.
  • In addition to glycoproteins that are commonly expressed by all of the cell lines, we identified others that are only expressed in the more well-differentiated thyroid cancer cell lines (follicular, Hurthle cell and papillary), or by cell lines derived from undifferentiated tumors that are uniformly fatal forms of thyroid cancer (i.e., anaplastic).

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SODIUM M-PERIODATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Matrix Biol. 2006 Sep;25(7):443-56 [16934444.001]
  • [Cites] Exp Oncol. 2007 Mar;29(1):54-60 [17431390.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Pathol. 2007 Aug;212(4):411-9 [17573672.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6777-85 [17638889.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5826-37 [17591751.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1666-77 [17727684.001]
  • [Cites] Dev Biol. 2007 Oct 15;310(2):291-303 [17822691.001]
  • [Cites] Biophys J. 2008 Feb 15;94(4):1326-40 [17933878.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):818-23 [18212751.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1572-80 [18316623.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1313-24 [18257091.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):194-200 [18353626.001]
  • [Cites] Mol Cell Proteomics. 2008 May;7(5):825-44 [17913849.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):577-80 [18617884.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):528-33 [18664479.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):4079-88 [18665625.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32802-11 [18718903.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1215-33 [18217975.001]
  • [Cites] Mol Cell Proteomics. 2009 Feb;8(2):287-301 [18923192.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2840-52 [15837731.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Electrophoresis. 2002 Sep;23(18):3205-16 [12298092.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(20):2310-6 [14558131.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:397-422 [14570575.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11222-6 [1722323.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1991-6 [8364879.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] Endocr Rev. 1999 Apr;20(2):207-39 [10204118.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Mol Cancer. 2004 Nov 17;3:31 [15548330.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1713-21 [15755992.001]
  • [Cites] Thyroid. 2005 Sep;15(9):1011-20 [16187909.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 [16314869.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2070-80 [16335952.001]
  • [Cites] Surgery. 2005 Dec;138(6):1102-9; discussion 1109-10 [16360397.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):226-33 [16263699.001]
  • [Cites] J Pathol. 2006 Mar;208(4):453-61 [16470907.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2918-22 [16540638.001]
  • [Cites] Histopathology. 2006 Apr;48(5):612-4 [16623792.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):845-57 [16467180.001]
  • [Cites] Cancer Control. 2006 Apr;13(2):99-105 [16735983.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18257-63 [16648631.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1638-47 [16646078.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):485-9 [16930327.001]
  • [Cites] Surg Oncol. 2006 Jul;15(1):43-55 [16950080.001]
  • [Cites] Cesk Patol. 2006 Jul;42(3):120-4 [16955558.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19530676.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / MD000544-06; United States / NIGMS NIH HHS / GM / R25 GM048972; United States / NIMHD NIH HHS / MD / P20 MD000544; United States / NIMHD NIH HHS / MD / P20 MD000544-06; United States / NIGMS NIH HHS / GM / GM048972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Hydrazines; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 10450-60-9 / Periodic Acid; B45A1BUM4Q / metaperiodate; EC 3.5.1.52 / Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
  • [Other-IDs] NLM/ NIHMS132564; NLM/ PMC2735218
  •  go-up   go-down


41. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, Zhang H, Wiseman SM: Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg; 2006 May;191(5):593-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm.
  • BACKGROUND: The objective of this study was to evaluate the cancer risk of patient clinicopathologic characteristics to determine the optimal approach for the surgical management of individuals with Hurthle cell neoplasm (HN) diagnosed by cytology.
  • The association of these characteristics with a pathologic cancer diagnosis was evaluated using Fisher's exact test and Student t test.
  • RESULTS: Of the 422 patients undergoing thyroidectomy, 27 presented with a fine-needle aspiration biopsy diagnosis of HN, and by pathologic assessment 7 HN patients (25.9%) had a cancer diagnosis.
  • Although none of the clinicopathologic characteristics evaluated were able to reliably differentiate benign from malignant tumors, large tumor size and male sex were significantly associated with a pathologic diagnosis of Hurthle cell carcinoma (P < .05).
  • CONCLUSIONS: Hemithyroidectomy represents the preferred initial surgical approach for the management of individuals presenting with nodular thyroid disease and a cytologic diagnosis of HN.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647343.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Chao TC, Lin JD, Chen MF: Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg; 2005 Feb;29(2):164-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Hurthle cell tumors of the thyroid.
  • Hurthle cell tumors are relatively rare thyroid tumors and their management and prognosis is controversial.
  • We retrospectively review 135 Hurthle cell adenomas and 28 Hurthle cell carcinomas of the thyroid surgically treated at our institute.
  • No significant difference was found between the adenoma and carcinoma groups in patient age, gender, and tumor size.
  • Meanwhile, most of the carcinoma patients underwent total thyroidectomy.
  • No recurrence of Hurthle cell adenomas was noted.
  • Five adenoma patients died of causes unrelated to their Hurthle cell tumors, but no carcinoma patients died during the follow-up period.
  • In conclusion, clinical factors and FNAC are not helpful in the differentiation between adenoma and carcinoma.
  • Unilateral Hurthle cell adenoma can be treated by lobectomy/isthmusectomy, and Hurthle cell carcinoma can be treated by total thyroidectomy with minimal operative morbidity.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650796.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G: Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res; 2006 Jun 15;66(12):6087-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.
  • Oncocytic tumors are characterized by cells with an aberrant accumulation of mitochondria.
  • To assess mitochondrial function in neoplastic oncocytic cells, we studied the thyroid oncocytic cell line XTC.UC1 and compared it with other thyroid non-oncocytic cell lines.
  • Osteosarcoma-derived transmitochondrial cell hybrids (cybrids) carrying XTC.UC1 mitochondrial DNA (mtDNA) were generated to discriminate whether the energetic failure depended on mitochondrial or nuclear DNA mutations.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. DNA, Mitochondrial / genetics. Electron Transport Complex I / genetics. Electron Transport Complex III / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Bone Neoplasms / enzymology. Bone Neoplasms / genetics. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Cell Line, Tumor. Cell Survival / physiology. Humans. Osteosarcoma / enzymology. Osteosarcoma / genetics. Osteosarcoma / metabolism. Osteosarcoma / pathology. Oxidative Phosphorylation. Reactive Oxygen Species / metabolism


44. Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, Palmieri EA, Conzo G, Papotti M, Palombini L: Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer; 2009 Dec 25;117(6):522-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms.
  • BACKGROUND: Thyroid fine-needle aspiration (FNA) samples that feature a follicular-patterned, monotonous Hurthle (oncocytic) cell population cannot be diagnosed reliably.
  • The authors of this report recently identified cyclin D3 overexpression on histologic sections of Hurthle cell carcinoma.
  • METHODS: Fifty-one FNA samples that were suspicious for Hurtle cell neoplasia and that had histologic follow-up (19 malignant cases) were examined.
  • Cyclin D3 expression levels were evaluated in cell block preparations and were compared with levels of the closely related cyclin D1 protein.
  • Cyclin D1 and cyclin D3 were highly specific (100% for both) and fairly accurate (75% and 92%, respectively) in distinguishing between benign and malignant oncocytic lesions; the positive predictive value (PPV) for each was 100%.
  • CONCLUSIONS: Cyclin D3 increased the suspicion of malignancy in indeterminate oncocytic lesions; its diagnostic performance depended on the cutoff point used and was enhanced further when combined with cyclin D1.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Cyclin D1 / metabolism. Cyclin D3 / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19787802.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin D3; 136601-57-5 / Cyclin D1
  •  go-up   go-down


45. Bouasker I, Zoghlami A, Farah Klibi F, Smaali I, El Ouaer MA, Zermani R, Dziri C: Adreno-cortical oncocytoma: a case report. Tunis Med; 2010 May;88(5):353-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adreno-cortical oncocytoma: a case report.
  • BACKGROUND: Adrenal oncocytoma is a very rare lesion, non functioning and benignin most cases.
  • AIM: This study aimed to report a new case of adrenal oncocytic tumor with uncertain malignant potential.
  • The diagnosis of adrenal oncocytoma with malignant potential was confirmed by pathology.
  • CONCLUSION: Adreno cortical oncocytoma is a rare tumor.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Gland Neoplasms / pathology. Kidney Cortex / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517834.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


46. Yaturu S, Rainer L: Thyroid nodule with eggshell calcification and oncocytic thyroid cancer. Med Sci Monit; 2010 Mar;16(3):CS25-28
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid nodule with eggshell calcification and oncocytic thyroid cancer.
  • BACKGROUND: To report an interesting case of Hurthle cell cancer of the thyroid with eggshell calcification, including ultra-sonographic, surgical, histological, and immuno-histochemical findings and discussion of diagnostic and therapeutic strategies.
  • US-guided FNA revealed a richly cellular specimen with numerous sheets of Hurthle cells with nuclear pleomorphism and intranuclear vacuoles.
  • Microscopic examination revealed oncocytic or Hurthle cell carcinoma with pericapsular and vascular invasion.
  • We could not find any reports of Hurthle cell thyroid cancer with such coarse or eggshell calcification.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190688.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


47. Brocks BA, Peeters ME, Kimpfler S: Oncocytoma in the mandibular salivary gland of a cat. J Feline Med Surg; 2008 Apr;10(2):188-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma in the mandibular salivary gland of a cat.
  • Initial investigations suggested a malignant salivary gland tumour, and the mass was removed by extracapsular resection of the mandibular gland.
  • Histopathology showed an oncocytoma within the salivary gland.
  • An oncocytoma is a neoplastic transformation of oncocytes.
  • Physiological proliferation occurs next to oncocytosis, oncocytoma, and oncocytic carcinoma.
  • This is the first report of an oncocytoma in a feline mandibular salivary gland, and the first report of long-term survival after surgical removal.
  • [MeSH-major] Adenoma, Oxyphilic / veterinary. Cat Diseases / diagnosis. Salivary Gland Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160323.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Zagólski O, Czajecki K, Gajda M: [Diffuse hyperplastic oncocytosis of the parotid gland]. Pol Merkur Lekarski; 2006 Oct;21(124):356-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The WHO classification of salivary gland diseases considers 3 oncocytic lesions: oncocytosis, oncocytoma and oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Parotid Gland / pathology. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205777.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


49. Sav A, Scheithauer BW, Mazzola CA, Ketterling SR, Thompson SJ, Reilly MH: Oncocytic choroid plexus carcinoma: case report. Clin Neuropathol; 2010 Jan-Feb;29(1):14-20
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic choroid plexus carcinoma: case report.
  • Herein, we report an unusual choroid plexus carcinoma with extensive oncocytic transformation.
  • Microsections revealed a WHO Grade III choroid plexus carcinoma with extensive oncocyti c transformation.
  • A minor portion of the moderately to poorly differentiated tumor exhibited classical microscopic features of choroid plexus carcinoma, including marked nuclear atypia, brisk mitotic activity (78/10 HPF), a high MIB-1 labeling index (44%) and zones of necrosis.
  • In contrast, the large, eosinophilic, cytologically malignant but granular-appearing oncocytes comprising the majority of the lesion showed scant (1/10 HPF) mitotic activity and only a low MIB-1 labeling index (5%).
  • A subsequent recurrence at 1 year consisted entirely of non-oncocytic tumor.
  • Choroid plexus carcinoma with oncocytic transformation has not been previously reported.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain / pathology. Carcinoma / pathology. Choroid Plexus Neoplasms / pathology
  • [MeSH-minor] Family. Female. Humans. Infant. Magnetic Resonance Imaging. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040328.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Elliott DD, Pitman MB, Bloom L, Faquin WC: Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer; 2006 Apr 25;108(2):102-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
  • BACKGROUND: Lesions of the thyroid gland composed of Hurthle cells encompass pathologic entities ranging from hyperplastic nodules with Hurthle cell metaplasia to Hurthle cell carcinomas.
  • Many cytologic features of Hurthle cell lesions that distinguish neoplastic Hurthle cell lesions requiring surgery from those that are benign and nonneoplastic have been described, but with variable usefulness.
  • A morphologic study was made of 139 Hurthle cell lesions of the thyroid gland and statistical analysis applied to identify a set of cytomorphologic features that distinguish benign Hurthle cell lesions (BHCL) from Hurthle cell neoplasms (HCN).
  • METHODS: Fine-needle aspiration biopsies (FNABs) of thyroid nodules with a predominant Hurthle cell component and corresponding histologic followup were included in the study.
  • Cases were divided into BHCL and HCN groups on the basis of the histologic diagnosis.
  • All cases were reviewed to assess the following 14 cytologic features: overall cellularity, cytoarchitecture, percentage of Hurthle cells, percentage of single cells, percentage of follicular cells observed as naked Hurthle cell nuclei, background colloid, chronic inflammation, cystic change, transgressing blood vessels (TBV), intracytoplasmic lumina, presence of multinucleated Hurthle cells, nuclear to cytoplasmic ratio, nuclear pleomorphism/atypia, and nucleolar prominence.
  • Six of the 14 cytologic features evaluated were shown by univariate analysis to be statistically significant in predicting HCN: nonmacrofollicular architecture (P < 0.001), absence of background colloid (P < 0.001), absence of chronic inflammation (P < 0.001), presence of TBV (P < 0.001), > 90% Hurthle cells (P < 0.001), and >10% single Hurthle cells (P = 0.014).
  • CONCLUSIONS: In the current study of 139 FNAB specimens of thyroid Hurthle cell nodules, 14 cytologic features were examined and 6 were found to be statistically significant in identifying HCN.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cell Nucleus / pathology. Colloids / analysis. Cytoplasm / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16453320.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colloids
  •  go-up   go-down


51. Kunju LP, Wojno K, Wolf JS Jr, Cheng L, Shah RB: Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol; 2008 Jan;39(1):96-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
  • Papillary renal cell carcinoma (PRCC), a morphologically and genetically distinct subtype of RCC, is morphologically separated into 2 subtypes, type 1 and 2, for prognostic purposes.
  • Type 1 PRCC (single layer of small cells, scant pale cytoplasm) is more common and has a favorable prognosis compared with type 2 (pseudostratified high-grade nuclei, abundant eosinophilic/oncocytic cytoplasm).
  • All tumors demonstrated predominant papillary architecture, lined by cells with oncocytic cytoplasm, and nonoverlapping low Fuhrman grade nuclei (1 or 2).
  • These results suggest that these tumors are distinct from type 1 (owing to oncocytic cells) and type 2 (owing to low-grade nonstratified nuclei, low stage, and good outcome).
  • Awareness of this favorable spectrum of PRCC is important to avoid its potential misinterpretation as an aggressive type 2 PRCC (owing to oncocytic cells) or rarely as an oncocytoma (owing to oncocytic cells and low-grade nuclei).
  • Morphologic spectrum of these PRCCs emphasizes that the future prognostic model of PRCC may need to be based primarily on the nuclear characteristics, irrespective of the cytoplasmic features.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Chromosome Aberrations. Cytoplasm / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Trisomy


52. Pezzolla A, Lattarulo S, Milella M, Barile G, Pascazio B, Ciampolillo A, Fabiano G, Palasciano N: [Incidental carcinoma in thyroid pathology: our experience and review of the literature]. Ann Ital Chir; 2010 May-Jun;81(3):165-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental carcinoma in thyroid pathology: our experience and review of the literature].
  • [Transliterated title] Il carcinoma incidentale nella patologia tiroidea. La nostra esperienza e revisione della letteratura.
  • The diagnosis of incidental thyroid carcinoma in patients submitted to thyroidectomy for a benign disease is quite frequent.
  • A retrospective analysis was performed on 240 patients submitted to surgical intervention in order to establish the incidence of the carcinoma.
  • One hundred sixty five patients (68.75%) were affected by benign disease (132 multinodular goiter, 30 uninodular goiter, 2 Plummer and 1 Basedow) and 75 (31.25%) by carcinoma.
  • In 30 of 165 patients (18.2 %), affected by benign disease, occurred a histological diagnosis of thyroid carcinoma, (18 papillary carcinoma, 6 follicular carcinoma, 5 papillary carcinoma follicular variant and 1 oncocytic carcinoma).
  • In this study it's considered incidental thyroid carcinoma the one occurred in patients who never underwent FNA and there were no suspicious features in all exams that may suggest the presence of carcinoma.
  • Fifteen of the 30 incidental carcinoma (50%) were microcarcinomas; in the other 13, dimensions were more than 1 cm, but less than 2 cm in 9 cases.
  • Two patients had a synchronous carcinoma.
  • This study shows that the only way to put doubts on the real benignity of the disease is the fine needle aspiration; there are no other instruments that could let think about the occurrence of the carcinoma.
  • Moreover in the majority of cases the incidental carcinoma is a microcarcinoma, it doesn't reach significant volume, may be not centered by a FNAB, but in must cases it's not really biologically aggressive.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Incidental Findings. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Goiter, Nodular / pathology. Graves Disease / pathology. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Plummer-Vinson Syndrome / pathology. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105480.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


53. Shomaf MS, Younes NA, Albsoul NM, Musmar AA, Al-Zaheri MM, Tarawneh MS, Sroujieh AS: New trends in the clinicopathological features of differentiated thyroid cancer in Central Jordan. Saudi Med J; 2006 Feb;27(2):185-90
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed the clinical features, management and outcome of 110 patients diagnosed with thyroid carcinoma at Jordan University Hospital, Amman, between 1996 and 2001.
  • RESULTS: Papillary carcinoma was diagnosed in 87 patients (80%), follicular carcinoma in 3 patients (2.7%), Hurthle cell carcinoma in 8 patients (7.3%), medullary carcinoma in 5 (4.5%), and anaplastic carcinoma in 4 patients (3.6%), metastatic cancer in 2 patients and lymphoma in one patient.
  • All patients with follicular carcinoma were diagnosed in the period 1986-1994.
  • After thyroidectomy and a follow up period of 2-15 years, 10 patients died of their disease, 4 of these died within one year from anaplastic thyroid carcinoma.
  • CONCLUSION: The dramatic decline in the incidence of follicular thyroid carcinoma combined with the increase in the advanced forms of thyroid cancer in Central Jordan may suggest a possible environmental factor in thyroid carcinogenesis in this region.
  • [MeSH-minor] Adult. Aged. Carcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Carcinoma, Papillary / epidemiology. Female. Humans. Jordan / epidemiology. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501673.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


54. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


55. Perepletchikov AM, Alroy J, Ucci A: Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features. Pathol Res Pract; 2010 Jun 15;206(6):384-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features.
  • No currently defined imaging techniques can reliably distinguish between oncocytoma and epithelial malignant lesions with oncocytic features in the kidney; therefore, patients must undergo resection or, in certain circumstances, biopsy to definitively establish diagnosis.
  • Immunohistochemical staining for CD10 and CD3, evaluation of the staining pattern and intensity, and relevant morphologic appearance are helpful diagnostic tools in discriminating between renal cell carcinoma with oncocytic features and renal oncocytoma.
  • Electron microscopy confirms different ultrastructural components of each neoplastic cell type and correlates with immunohistochemical findings.
  • [MeSH-major] Antigens, CD3 / biosynthesis. Carcinoma, Renal Cell / ultrastructure. Kidney Neoplasms / ultrastructure. Neprilysin / biosynthesis
  • [MeSH-minor] Adenoma, Oxyphilic. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier GmbH.
  • (PMID = 19942355.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


56. Camargo RS, Maeda MY, di Loreto C, Shirata NK, Anselmo Garcia E, Filho AL: Is agNOR and DNA ploidy analysis useful for evaluating thyroid neoplasms? Anal Quant Cytol Histol; 2005 Jun;27(3):157-61
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Eighty-one consecutive cases of thyroid carcinoma were selected for DNA and AgNOR analysis.
  • The diagnoses were: papillary carcinoma (n = 40), follicular carcinoma (n = 31), Hürthle cell adenocarcinoma (n = 4), and undifferentiated carcinoma (n = 6).
  • Counting the NORs was performed by subjectively counting the NORs in 200 malignant cells.
  • RESULTS: DNA ploidy analysis showed all Hürthle cell adenocarcinomas, 21 (67%)follicular tumors, 23 (57%) papillary tumors and 4 (67%) undifferentiated carcinomas to be aneuploid.
  • Statistical analysis showed correlation between ploidy and histologic diagnosis, but not AgNOR counting, to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121637.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


57. Kuroda N, Tamura M, Taguchi T, Tominaga A, Hes O, Michal M, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Shuin T, Lee GH: Sarcomatoid acquired cystic disease-associated renal cell carcinoma. Histol Histopathol; 2008 11;23(11):1327-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid acquired cystic disease-associated renal cell carcinoma.
  • In this article, we report a rare case of hitherto undescribed acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) with sarcomatoid change.
  • Microscopically, oncocytic cuboidal cells proliferated with tubular, cribriform or papillary growth patterns, and atypical columnar cells with abundant cytoplasm proliferated with papillary configuration.
  • The cytoplasm of oncocytic and sarcomatous neoplastic cells was diffusely positive for anti-mitochondrial antibody and the ultrastructural examination detected many mitochondria in the cytoplasm of oncocytic carcinoma cells and sarcomatous neoplastic cells.
  • We thus report here a case of hitherto undescribed ACD-associated RCC intermingled with oncocytic cells, translocation type RCC-like area and sarcomatoid change.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / complications. Kidney Failure, Chronic / etiology. Kidney Neoplasms / etiology. Sarcoma / etiology
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Nephrectomy. Nucleic Acid Hybridization. Oxyphil Cells / ultrastructure. Renal Dialysis


58. Chahwala Q, Siddaraju N, Singh N, Goneppanavar M, Basu D: Fine needle aspiration cytology of oncocytic lipoadenoma of the parotid gland: report of a rare case. Acta Cytol; 2009 Jul-Aug;53(4):437-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of oncocytic lipoadenoma of the parotid gland: report of a rare case.
  • BACKGROUND: Oncocytic lipoadenoma is an uncommon benign salivary gland tumor.
  • Fine needle aspiration cytologic (FNAC) findings of oncocytic lipoadenoma have not yet been documented.
  • FNAC showed moderate cellularity, with oncocytic cells arranged predominantly as microacini in a prominent lipoid background.
  • The adipose tissue background of the cytologic smears was ignored as material derived from the normal fat tissue; based on the oncocytic population of cells, a diagnosis of oncocytoma was considered.
  • A remote possibility of acinic cell carcinoma with oncocytic features was also suggested.
  • However, histopathologic examination showed it to be an oncocytic lipoadenoma, a tumor we were unaware of at the time of cytodiagnosis.
  • CONCLUSION: Both cytopathologists and histopathologists need to be aware of oncocytic lipoadenoma of the salivary gland in order to diagnose it precisely.
  • The clinicocytopathologic correlation highlighted in our case will be useful for cytopathologists in preoperative interpretation and diagnosis.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697732.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y: Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene; 2005 Jun 9;24(25):4155-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma.
  • The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood.
  • To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology.
  • A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma.
  • Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication.
  • Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism.
  • Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Papillary / genetics. Gene Expression Profiling / methods. Oncogenes. Signal Transduction / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Actinin / genetics. Cell Communication / genetics. Cytoskeletal Proteins / genetics. Humans. Nitric Oxide Synthase / genetics. Nitric Oxide Synthase Type III. Reverse Transcriptase Polymerase Chain Reaction. alpha Catenin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806164.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / Cytoskeletal Proteins; 0 / alpha Catenin; 11003-00-2 / Actinin; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


60. Al-Shraim MM, Hussein MR, Musalam AO, Al-Ghandi T, Al-Zahramit H, Mahrouz AA, Abu-Eshy SA: Hurthle cell neoplasms of thyroid in south-western region of Saudi Arabia. West Afr J Med; 2010 Nov-Dec;29(6):398-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell neoplasms of thyroid in south-western region of Saudi Arabia.
  • BACKGROUND: Thyroid Hurthle cell neoplasm (THCN) is relatively rare.
  • METHODS: This was a retrospective chart review of all thyroid Hurthle cell neoplasms diagnosed at Aseer Central Hospital (ACH), Saudi Arabia during the period from October 1998 to April 2007.
  • Three cases were Hurthle cell carcinomas and six cases were Hurthle cell adenomas.
  • Carcinomas presented as solitary nodules (two cases) and as multinodular goiter (one case).
  • Fine needle aspiration cytology (FNAC) was diagnostic for THCN in two cases of carcinoma that presented as solitary nodules and hence total thyroidectomy was performed.
  • Hemithyroidectomy was performed in two cases of adenoma in which FNAC showed benign lesion and in one case of carcinoma based on clinical and ultrasonographic impression of benign MNG in the involved lobe and inconclusive FNAC result.
  • CONCLUSION: Preoperative diagnosis and management of THCN is still a dilemma.
  • Neither clinical nor FNAC findings can exclude carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21465448.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] Thyroid cancer, Hurthle cell
  •  go-up   go-down


61. Quinn TR, Duncan LM, Zembowicz A, Faquin WC: Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature. Am J Dermatopathol; 2005 Aug;27(4):306-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature.
  • Cutaneous metastasis of follicular carcinoma of the thyroid is very rare, and when it occurs, can exhibit a variety of histologic appearances.
  • The cases consisted of 4 patients, 3 men and 1 woman, aged 52 to 75 years, with cutaneous metastasis of follicular thyroid carcinoma.
  • The tumors include a conventional follicular carcinoma, a follicular carcinoma with anaplastic transformation following initial metastasis, the first reported cutaneous metastases of a follicular carcinoma with oncocytic features (Hürthle cell carcinoma), and a follicular carcinoma with a prominent insular carcinoma component.
  • Three metastases retained the morphologic and immunocytochemical features of the primary thyroid tumors.
  • However, in one case there was high-grade transformation to anaplastic carcinoma following treatment of a sacral metastasis with accompanying loss of the characteristic immunophenotype of follicular thyroid carcinoma.
  • Awareness of the varied morphologies of metastatic follicular thyroid carcinoma to the skin may prompt immunohistochemical analysis and the request for a complete clinical history, ultimately preventing misdiagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Skin Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121050.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Argyriou P, Zisis C, Alevizopoulos N, Kefaloyannis EM, Gennatas C, Petraki CD: Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature. World J Surg Oncol; 2008;6:134
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature.
  • BACKGROUND: Adrenal cortex oncocytic carcinoma (AOC) represents an exceptional pathological entity, since only 22 cases have been documented in the literature so far.
  • CASE PRESENTATION: Our case concerns a 54-year-old man with past medical history of right adrenal excision with partial hepatectomy, due to an adrenocortical carcinoma.
  • CONCLUSION: Histological classification of adrenocortical oncocytic tumours has been so far a matter of debate.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Sep;166(3):985 [11490264.001]
  • [Cites] J Assoc Physicians India. 1999 Mar;47(3):351-2 [10999143.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Int J Surg Pathol. 2003 Jul;11(3):229-34 [12894359.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):603-10 [15260851.001]
  • [Cites] Urology. 2004 Aug;64(2):376-7 [15302503.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1985 Jul;9(7):517-24 [3004244.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Mod Pathol. 1993 Nov;6(6):663-8 [7508113.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):556-62 [9158680.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):91-7 [10452574.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):105-16 [10452576.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):146-61 [10452580.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):190-9 [10452583.001]
  • [Cites] Ultrastruct Pathol. 2005 Sep-Oct;29(5):399-404 [16257866.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):14-21 [16234301.001]
  • [Cites] Virchows Arch. 2006 Feb;448(2):228-31 [16450120.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1039-43 [16467161.001]
  • [Cites] Pathol Int. 2006 Dec;56(12):755-9 [17096734.001]
  • [Cites] Neth J Med. 2007 Feb;65(2):55-60 [17379929.001]
  • [Cites] J Cutan Pathol. 2007 Apr;34(4):355-9 [17381809.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):677-80 [17591040.001]
  • [Cites] Pathologe. 2007 Jul;28(4):281-4 [16673076.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Jun;115(6):401-4 [17701888.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):187-9 [18058268.001]
  • [Cites] Urol Oncol. 2008 Mar-Apr;26(2):198-201 [18312941.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):299-303 [10790237.001]
  • [Cites] Arch Esp Urol. 2001 Dec;54(10):1123-6 [11852522.001]
  • (PMID = 19091123.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2630932
  •  go-up   go-down


63. Pino Rivero V, González Palomino A, Trinidad Ruíz G, Keituqwa Yáñez T, Marcos García M, Pardo Romero G, Pantoja Hernández CG, Blasco Huelva A: [Hürthle cells carcinoma. Report of two operated cases and review of the literature]. An Otorrinolaringol Ibero Am; 2005;32(5):467-73
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hürthle cells carcinoma. Report of two operated cases and review of the literature].
  • [Transliterated title] Carcinoma de células de hürthle. Descripción de dos casos intervenidos y revisión de la literatura.
  • Hürthle cells carcinomas are considered a variant of folicular carcinomas and represent about 2% of all malignant thyroid tumours.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318090.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


64. Mwandila M, Waller H, Stott V, Mercer P: A case of a testosterone-secreting oncocytic adrenocortical carcinoma. N Z Med J; 2010 Nov 5;123(1325):80-2
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • Oncocytic neoplasms are most rarely found in the adrenal gland.
  • We present a case of a testosterone-secreting oncocytic adrenocortical carcinoma in a 19-year-old female who presented with acne, hirsutism and irregular menses.
  • The histology showed the tumour to be comprised of oncocytic cells with granular, eosinophilic cytoplasm, features consistent with an oncocytic carcinoma.
  • This is the first case presented of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Adrenocortical Carcinoma / secretion. Testosterone / secretion
  • [MeSH-minor] Adrenalectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21317966.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


65. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simões M: Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer; 2005 May 23;92(10):1892-8
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.
  • Oxyphil or Hurthle cell tumours of the thyroid are characterised by their consistent excessive number of mitochondria.
  • A recently discovered gene, GRIM-19 has been found to fulfil two roles within the cell: as a member of the interferon-beta and retinoic acid-induced pathway of cell death, and as part of the mitochondrial Complex I assembly.
  • In addition, a gene predisposing to thyroid tumours with cell oxyphilia (TCO) has been mapped to chromosome 19p13.2 in one family.
  • Somatic missense mutations in GRIM-19 were detected in three of 20 sporadic Hurthle cell carcinomas.
  • A germline mutation was detected in a Hurthle cell papillary carcinoma arising in a thyroid with multiple Hurthle cell nodules.
  • No mutations were detected in any of the 20 non-Hurthle cell carcinomas tested, nor in any of 96 blood donor samples.
  • In one of the sporadic Hurthle cell papillary carcinomas positive for GRIM-19 mutation, we have also detected a ret/PTC-1 rearrangement.
  • No GRIM-19 mutations were detected in any of the six cases of known familial Hurthle cell tumour tested, so that our results do not support the identification of GRIM-19 as the TCO gene.
  • The GRIM-19 mutations we have detected are the first nuclear gene mutations specific to Hurthle cell tumours to be reported to date; we propose that such mutations can be involved in the genesis of sporadic or familial Hurthle cell tumours through the dual function of GRIM-19 in mitochondrial metabolism and cell death.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / physiopathology. Mitochondria / metabolism. Mitochondria / pathology. NADH, NADPH Oxidoreductases / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13221-7 [8675499.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2108-17 [9528783.001]
  • [Cites] J Pathol. 1998 May;185(1):71-8 [9713362.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6493-504 [9774665.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4116-22 [9814501.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6670-7 [9822610.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1743-8 [9837827.001]
  • [Cites] J Pathol. 1998 Nov;186(3):292-9 [10211119.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:1019-27 [13904230.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):2060-6 [10803467.001]
  • [Cites] J Interferon Cytokine Res. 2000 Jul;20(7):661-5 [10926209.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33416-26 [10924506.001]
  • [Cites] J Pathol. 2000 Dec;192(4):561-2 [11113879.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):95-9 [11452314.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38345-8 [11522775.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4715-21 [12364463.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):938-41 [12574236.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1325-35 [12628925.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Mol Endocrinol. 2003 Jun;17(6):1155-66 [12637586.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9342-7 [12867595.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8447-56 [15367666.001]
  • [Cites] Ultrastruct Pathol. 1985;8(2-3):131-42 [4060255.001]
  • [Cites] Ultrastruct Pathol. 1985;8(4):269-90 [4082297.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Cytogenet Cell Genet. 1994;66(4):253-9 [7909283.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Biochim Biophys Acta. 1995 May 24;1271(1):241-8 [7599215.001]
  • [Cites] Science. 1996 May 3;272(5262):719-22 [8614832.001]
  • [CommentIn] Br J Cancer. 2005 May 23;92(10):1817-8 [15900303.001]
  • (PMID = 15841082.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Protein Subunits; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.5.- / GRIM19 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2361763
  •  go-up   go-down


66. Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B: PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab; 2005 Jan;90(1):463-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.
  • The PAX8/PPARgamma (PPFP) fusion-oncogene is moderately specific for follicular thyroid carcinomas (FTC).
  • It remains unknown whether this can be translated into improved diagnosis, classification, or outcome prediction.
  • We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hurthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARgamma immunohistochemistry (as a surrogate of PAX8/PPARgamma expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section.
  • PPARgamma staining was associated with favorable prognostic indicators (female gender, better tumor differentiation, and lesser risk of metastases).PPARgamma staining may be helpful in the differential diagnosis of FA, FTC, and HCC, particularly when diagnostic sensitivity of histomorphology is reduced (e.g. during intraoperative frozen section).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15483076.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA80117
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Recombinant Fusion Proteins; 0 / Trans-Activators
  •  go-up   go-down


67. Aslam MI, Spencer L, Garcea G, Pollard C, Metcalfe MS, Harrison RF, Dennison AR: A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing. Int J Surg Pathol; 2009 Apr;17(2):158-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of liver metastasis from an oncocytoma with a focal area of chromophobe renal cell carcinoma: a wolf in sheep's clothing.
  • There are reports of subtypes of renal tumors, with similar histological morphology to oncocytoma, but with malignant potential, one of these tumors is the eosinophilic variant of chromophobe renal cell carcinoma.
  • A rare case of a liver metastasis from a focal area of eosinophilic variant of chromophobe renal cell carcinoma mixed in oncocytoma in a 69-year-old woman is reported.
  • Although some renal tumors may contain oncocytoma and eosinophilic variant of chromophobe renal cell carcinoma histology, caution should be exercised while diagnosing oncocytomas in needle biopsies as there may be unsampled area of chromophobe carcinoma which has a potential for metastatic spread representing a wolf in sheep's clothing.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Liver Neoplasms / secondary


68. Zhou CX, Shi DY, Ma DQ, Zhang JG, Yu GY, Gao Y: Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases. Oral Oncol; 2010 Oct;46(10):773-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic carcinoma of the salivary glands: a clinicopathologic and immunohistochemical study of 12 cases.
  • Oncocytic carcinoma (OC) of salivary gland origin is an extremely rare proliferation of malignant oncocytes with adenocarcinomatous architectural phenotypes, including infiltrative qualities.
  • In summary, OC of salivary gland origin is a high-grade tumor, often with local recurrence, regional or distant metastasis, diagnosis of which based on a combination of clinical and histopathological features.
  • Immunohistochemistry for mitochondria is considered as a practical and helpful adjuvant diagnosis.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20843731.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA: Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol; 2010 Jan;133(1):133-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases.
  • Sixteen cases of primary oncocytic adenocarcinomas of the lung are reported.
  • Histologically, all the cases displayed prominent oncocytic features with conventional growth patterns, including acinar, papillary, and bronchioloalveolar.
  • These cases represent an unusual variant of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023269.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


70. Manxhuka-Kerliu S, Devolli-Disha E, Gerxhaliu A, Ahmetaj H, Baruti A, Loxha S, Thaqi H: Prognostic values of thyroid tumours. Bosn J Basic Med Sci; 2009 May;9(2):111-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular adenomas have been found in 39, 1% of cases, thyroid carcinomas in 60, 12%, whereas thyroid secondary carcinomas have been found in 0, 72% of cases.
  • As far as histological variants of thyroid carcinomas are concerned, most frequently found were papillary carcinomas in 39,85% of cases; followed by follicular carcinomas in 9,42% of cases; follicular variants of papillary carcinomas in 5,79% of cases; medullary carcinomas in 3,62% of cases, while anaplastic and Hurthle cell carcinomas have been found in 0,72% of cases each.
  • Papillary carcinoma has been found in 80% of female cases.
  • Our data indicate that apart from the fact that papillary carcinomas, well differentiated, and characterised by relatively good prognosis, were most frequent variants, certain morphological variants of it were associated with poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485942.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


71. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE: Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol; 2007 May;31(5):729-36
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
  • We describe the histologic variants of papillary and follicular carcinomas associated with 109 spindle and giant cell carcinomas (SGCC) of the thyroid and determine the incidence of rhabdoid and thyroglobulin inclusions in these tumors.
  • In addition, we searched for rhabdoid and thyroglobulin inclusions in 120 papillary carcinomas (PC) (all 15 variants included), 23 differentiated follicular carcinomas (DFC), (6 with insular pattern), 6 poorly differentiated follicular carcinomas (PDFC) and 34 follicular adenomas (FA).
  • The following differentiated thyroid carcinomas coexisted with SGCC: 51 (46.8%) PC, (34 conventional type, 14 tall cell variant and 3 follicular variant), 6 (5.5%) DFC, 1 follicular carcinoma with insular pattern (0.9%), and 3 oncocytic carcinomas (2.8%).
  • Thyroglobulin inclusions were found in 10 FA (29%), 8 (17%) follicular variants of PC and in 7 (30.4%) DFC.
  • The finding that only 1 (0.9%) SGCC was associated with follicular carcinoma with insular pattern contradicts the opinion that this tumor occupies an intermediate position between differentiated and anaplastic carcinomas.
  • Rhabdoid features are markers of PDFC and SGCC while thyroglobulin inclusions are markers of FA and differentiated thyroid carcinomas with follicular phenotype.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Carcinoma, Papillary, Follicular / pathology. Inclusion Bodies / pathology. Rhabdoid Tumor / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460457.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


72. Little JW: Thyroid disorders. Part III: neoplastic thyroid disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep;102(3):275-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of these tumors are benign hyperplastic or colloid nodules or benign follicular adenomas.
  • However, 5% to 10% of the lesions that come to medical attention are carcinomas.
  • A major clinical challenge is establishing which nodules are hyperplastic, benign, or malignant.
  • History, clinical findings, ultrasonography, and fine-needle aspiration biopsy are the mainstays for diagnosis.
  • Differentiated lesions are subdivided into papillary, follicular, and Hurthle cell carcinomas.
  • An important neoplastic syndrome, multiple endocrine neoplasia type 2 (MEN2), involves medullary carcinoma of the thyroid gland.
  • The overall 10-year survival for papillary carcinoma is 80% to 90%, follicular carcinoma 65% to 75%, and medullary carcinoma 60% to 70%.
  • The prognosis for anaplastic carcinoma is very poor and 5-year survival is rare.
  • The dentist by inspection and palpation of the neck in the area of the thyroid gland may detect single or multiple lesions that may be benign or malignant.
  • Patients with identified nodules or enlarged thyroid glands should be referred for diagnosis and treatment.
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Carcinoma / blood. Carcinoma / diagnosis. Carcinoma, Medullary / blood. Carcinoma, Medullary / diagnosis. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920533.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A: HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol; 2010 Oct 25;118(5):287-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
  • BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine-needle aspiration (FNA) (eg, "suspicious for follicular neoplasm") prove to be benign at the time of surgical resection.
  • Ancillary tests in current use are limited in their ability to improve the preoperative detection of malignant follicular thyroid nodules.
  • Studies using paraffin-embedded tissue have indicated that high mobility group AT-hook 2 (HMGA2) overexpression is present in a high percentage of malignant thyroid neoplasms but not in benign thyroid neoplasms.
  • In the current study, the ability of HMGA2 overexpression analysis to preoperatively distinguish benign from malignant thyroid nodules by reverse transcriptase-polymerase chain reaction (RT-PCR) on suspicious cytologic smears was evaluated.
  • A subset of these patients who had a cytologic diagnosis of "suspicious" underwent HMGA2 expression analysis.
  • With an HMGA2 overexpression change of 5.9-fold or greater compared with a thyroid tumor cell line as a positive cutoff, the test was found to have the following overall performance for detecting malignant nodules: sensitivity of 71%, specificity of 97%, positive predictive value of 94%, and negative predictive value of 84%.
  • HMGA2 overexpression was found to have low sensitivity for detecting Hurthle cell carcinoma (33%).
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Cytodiagnosis / methods. Diagnosis, Differential. Female. Goiter / diagnosis. Goiter / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20597139.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / RNA, Messenger
  •  go-up   go-down


74. Lee TH, Lin YS, Lee WY, Wu TC, Chang SL: Malignant transformation of a benign oncocytoma of the submandibular gland: a case report. Kaohsiung J Med Sci; 2010 Jun;26(6):327-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a benign oncocytoma of the submandibular gland: a case report.
  • Oncocytic carcinoma arising in the submandibular gland is an extremely rare tumor and only 11 cases have been reported previously.
  • We report on a 51-year-old man with a previously benign oncocytoma in the submandibular gland that transformed from a benign morphology to malignant cellular atypia and mitosis.
  • To our knowledge, the current report is the first published case of a malignant transformation from benign oncocytoma to oncocytic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Cell Transformation, Neoplastic. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Cell Proliferation. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20538238.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


75. Raĭkhlin NT, Smirnova EA, Pavlovskaia AI, Rotin DL, Gurevich LE, Savelov NA: [Askenazi (Hurtle) cell tumors of the thyroid]. Arkh Patol; 2005 Nov-Dec;67(6):13-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Askenazi (Hurtle) cell tumors of the thyroid].
  • Oncocytic adenomas have primarily follicular structure; trabeculas, solid areas, necrosis are rare.
  • They may possess malignant potential as their malignant transformation occurs in 35% cases against 5% in adenomas of follicular cells.
  • Oncocytic follicular carcinomas can be hardly distinguished from oncocytic adenomas.
  • Tumors larger than 4-5 cm in diameter are considered to be malignant.
  • Oncocytic papillary carcinoma and oncocytic medullary carcinoma are rare.
  • The clinical course of oncocytic tumors is more aggressive than that of tumors from follicular cells.
  • Of key importance in differential diagnosis is electron microscopy (EM) and immunohistochemistry with antimitochondrial antibodies.
  • EM may be also useful in determination of the degree of oncocytic tumors maturation.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Mitochondria / pathology. Thyroid Gland / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / metabolism. Carcinoma, Papillary, Follicular / pathology. Cell Differentiation. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405013.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


76. Sibony M, Vieillefond A: [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology]. Ann Pathol; 2008 Oct;28(5):381-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology].
  • [Transliterated title] Les tumeurs du rein qui ne sont pas des carcinomes à cellules claires. Etat des lieux en 2008.
  • Non clear cell renal cell carcinomas represent almost 20% of all renal neoplasms.
  • Since molecular techniques are expensive, diagnosis still relies on morphological and immuno-histochemical criteria detailed hereby.
  • Papillary renal cell carcinomas are the most important group and its classification is more and more complex.
  • It encompasses low-grade papillary carcinomas (type 1 papillary renal cell carcinoma, oncocytic papillary renal cell carcinoma) and high-grade papillary carcinomas (type 2 papillary renal cell carcinoma, juvenile papillary carcinoma corresponding to renal carcinoma associated with Xp11.2 translocations and unclassified carcinomas).
  • Mucinous tubular and spindle cell carcinoma and tubulocystic carcinoma are new entities, actually considered by some authors as low-grade papillary carcinomas.
  • The so-called carcinoma of collecting ducts of Bellini and renal medullary carcinoma should be considered as intrarenal urothelial carcinoma or as high-grade papillary or unclassified carcinoma.
  • Sarcomatoid carcinoma derives from morphological progression of any type of renal cell carcinoma.
  • The group of oncocytomas/chromophobe renal cell carcinomas can be considered as a spectrum from benign (oncocytoma) to malignant neoplasm (chromophobe renal cell carcinoma).
  • In the latter situation, some cases of epithelioid angiomyolipoma (potentially malignant) have been described.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / classification. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma / classification. Carcinoma / genetics. Carcinoma / pathology. Chromosome Mapping. Chromosomes, Human. Humans. Immunohistochemistry. Kidney / pathology. Kidney Tubules, Collecting / pathology. Necrosis

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068393.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 84
  •  go-up   go-down


77. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Archival formalin-fixed, paraffin-embedded sections of 54 benign and 56 malignant tumours and 24 samples of normal and inflamed salivary gland tissue were studied immunohistochemically using an Envision/horseraddish peroxidase (HRP) technique.
  • RESULTS: In normal and inflamed salivary gland samples, E-cadherin was expressed at the membrane of acinar, myoepithelial and ductal cells located at cell-cell contact points.
  • Neoplastic epithelium in Warthin's tumours and in myoepithelial and oncocytic adenomas was strongly positive.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


78. Pezzolla A, Docimo G, Ruggiero R, Monacelli M, Cirocchi R, Parmeggiani D, Conzo G, Gubitosi A, Lattarulo S, Ciampolillo A, Avenia N, Docimo L, Palasciano N: [Incidental thyroid carcinoma: a multicentric experience]. Recenti Prog Med; 2010 May;101(5):194-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental thyroid carcinoma: a multicentric experience].
  • [Transliterated title] Il carcinoma incidentale della tiroide: esperienza multicentrica.
  • BACKGROUND: In recent years it has seen an increase of incidental thyroid carcinomas (ICs), most of the ICs are any microcarcinoma (MC).
  • RESULTS: Histological examination confirmed the diagnosis of benignity in 1339 cases.
  • In 168, however, we detected unexpected, incidental carcinoma (CI).
  • Of the 168 patients with incidental CT, 147 had papillary carcinomas, 12 follicular carcinomas, 5 follicular variant papillary carcinomas, 2 oncocytic carcinomas, 1 uncertain malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20590015.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


79. Krishnanand G, Kaur M, Rao RV, Monappa V: Oncocytic variant of mucoepidermoid carcinoma of submandibular gland: an unusual clinical and morphological entity. Indian J Pathol Microbiol; 2007 Jul;50(3):538-40
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic variant of mucoepidermoid carcinoma of submandibular gland: an unusual clinical and morphological entity.
  • In this case report we describe a rare tumor--Oncocytic variant of Mucoepidermoid carcinoma of the submandibular salivary gland with a review of the literature.
  • Oncocytic metaplasia in salivary glands is a benign change that is associated with increasing age and also seen in a few salivary gland neoplasms', which include oncocytoma, Warthin's tumor, and the rare, oncocytic carcinoma.
  • Oncocytic differentiation in mucoepidermoid carcinoma (MEC) is uncommon.
  • Only twelve well-documented cases of oncocytic MEC have been reported previously all of which occurred in the parotid gland.
  • To the best of our knowledge this is the first case of oncocytic mucoepidermoid carcinoma involving the submandibular salivary gland.
  • The recognition of this entity is important, since most of the other primary oncocytic lesions of the salivary gland are benign.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Submandibular Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883126.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 10
  •  go-up   go-down


80. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • The topic is first approached by considering the different growth patterns and cell types that may be encountered.
  • The distinction between a sex cord tumor and an endometrioid carcinoma with sex-cord-like patterns may be greatly aided by the triad of epithelial membrane antigen (EMA), inhibin, and calretinin, the latter two being typically positive and EMA negative in sex cord tumors, the converse being typical of endometrioid carcinoma.
  • It should be emphasized that granulosa cell tumors may be inhibin negative and, albeit less specific, calretinin is more reliable in evaluating this particular issue.
  • The well-known staining of the latter neoplasm for S-100 protein and HMB-45 may be very helpful in evaluating melanomas with follicular or other unusual patterns, a challenging aspect of ovarian tumor interpretation.
  • The most common monodermal teratoma, struma ovarii, usually has an overt follicular pattern and is easily recognized, but recognition of unusual appearances ranging from oxyphilic to clear cell to various patterns of malignant struma may be greatly aided by a thyroglobulin or TTF 1 stain.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • Immunostains may be very helpful in the evaluation of oxyphilic tumors and tumor-like lesions and in some unusual forms of clear cell neoplasia, such as clear cell struma, both subjects being reviewed herein.
  • Immunostains may highlight both the presence and extent of epithelial cells in a variety of circumstances, including microinvasive foci in cases of serous borderline tumors and mucinous carcinomas, and in determining the extent of carcinoma cells and reactive cells within mural nodules of mucinous neoplasms.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • The evaluation of ovarian cystic lesions may be aided by thyroglobulin or TTF 1 (cystic struma), glial fibrillary acid protein (ependymal cysts), and inhibin-calretinin (follicle cysts and unilocular granulosa cell tumors).
  • Stains for trophoblast markers may occasionally aid in the evaluation of germ cell tumors, although routine stains should usually suffice; they may be of academic interest in confirming trophoblastic differentiation in some high grade surface epithelial carcinomas.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


81. Chia WK, Sharifah NA, Reena RM, Zubaidah Z, Clarence-Ko CH, Rohaizak M, Naqiyah I, Srijit D, Hisham AN, Asmiati A, Rafie MK: Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms. Cancer Genet Cytogenet; 2010 Jan 1;196(1):7-13
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms.
  • At the present time, the differentiation between follicular thyroid carcinoma (FTC) and adenoma can be made only postoperatively and is based on the presence of capsular or vascular invasion.
  • The ability to differentiate preoperatively between the malignant and benign forms of follicular thyroid tumors assumes greater importance in any clinical setting.
  • In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization.
  • It is hereby concluded that 3p25 aneusomy or PAX8-PPARG translocation may play an important role in the molecular pathogenesis of follicular thyroid tumors.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963130.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


82. Srigley JR, Delahunt B: Uncommon and recently described renal carcinomas. Mod Pathol; 2009 Jun;22 Suppl 2:S2-S23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon and recently described renal carcinomas.
  • Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma.
  • Clear cell, papillary and chromophobe carcinomas account for 85-90% carcinomas seen in routine practice.
  • The remaining 10-15% of carcinomas consist of rare sporadic and hereditary tumors, some of which had been long recognized, but many of which only emerged as distinct entities in the decade leading up to the WHO publication.
  • Collecting-duct carcinoma is a rare, often lethal form of carcinoma.
  • Medullary carcinoma associated with sickle cell trait, has emerged as a distinctive tumor showing some overlapping features with upper tract urothelial carcinoma.
  • Mucinous tubular and spindle-cell carcinoma and tubulocystic carcinoma were earlier considered as patterns of low-grade collecting-duct carcinoma, but are now recognized as separate tumor entities.
  • Carcinomas associated with somatic translocations of TFE3 and TFEB comprise a significant proportion of pediatric renal carcinomas.
  • Oncocytoid renal carcinomas in neuroblastoma survivors was recognized as a unique tumor category in the WHO classification.
  • Renal carcinoma associated with end-stage renal disease is now recognized as having distinct morphological patterns and behavior.
  • In addition there is a group of rare recently described carcinomas, including clear cell papillary carcinoma, oncocytic papillary renal cell carcinoma, follicular renal carcinoma and leiomyomatous renal cell carcinoma.
  • It behooves the surgical pathologist to not only be capable of diagnosing the common forms of renal cancer, but also to be aware of the rare types of renal carcinoma, many of which have emerged in recent years.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494850.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


83. Eldahshan S, Celia A, Zeccolini G, Guerini A, Breda G: Laparoscopic transperitoneal adrenalectomy for adrenocortical oncocytoma. Arch Ital Urol Androl; 2008 Jun;80(2):82-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic transperitoneal adrenalectomy for adrenocortical oncocytoma.
  • Final pathology was adrenocortical oncocytoma with malignant potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683814.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. Djekidel M, Gordon M, Shah RB, Gross MD, Avram A: Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging. Thyroid; 2010 Apr;20(4):429-33
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging.
  • BACKGROUND: In general, thyroid carcinomas, when they behave aggressively, metastasize to lungs and occasionally to bone and brain.
  • Here we report, to the best of our knowledge, the first patient with Hurthle cell thyroid cancer and renal metastasis.
  • SUMMARY: The patient was a 75-year-old man who had a history of a total thyroidectomy 9 years previously for a right thyroid lobe Hurthle cell carcinoma.
  • Anatomic imaging characteristics favored a primary renal cell cancer with the additional evidence of renal vein invasion and thrombosis.
  • Histology later revealed a metastatic renal Hurthle cell cancer with positive thyroglobulin stains.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2010 Nov;20(11):1321; author reply 321-2 [21062198.001]
  • (PMID = 20373987.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


85. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor.
  • The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. History, 19th Century. History, 20th Century. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


86. Yang XY, Hu CX, Yang LZ, Zhao WC, Pan Y: [Hurthle cell thyroid tumor: an analysis of 28 cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Nov;45(11):908-11
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hurthle cell thyroid tumor: an analysis of 28 cases].
  • OBJECTIVE: To explore the clinical features and the combined treatment modality of Hurthle cell thyroid tumor (HCT).
  • Postoperative pathological examination showed that 22 cases were Hurthle cell adenomas and 6 cases were Hurthle cell carcinomas, 1 of them with cervical lymph node metastasis.
  • Twenty-one patients with Hurthle cell adenomas were followed up for 6 months to 7.5 years (with a median of 45 months) and 6 patients with Hurthle cell carcinomas for 3 to 8 years (with a median of 54 months), with no recurrence and death case.
  • CONCLUSIONS: HCT is a potential malignant neoplasm.
  • There are some difficulties in the diagnosis of HCT by frozen section.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215204.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Mihai R, Parker AJ, Roskell D, Sadler GP: One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma. Thyroid; 2009 Jan;19(1):33-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma.
  • Cytological criteria for benign (THY2) and malignant (THY5) aspirates are well established and reliable.
  • When cytology suggests a follicular neoplasm (THY3), only formal histological assessment can differentiate between benign and malignant lesions.
  • The objective of this study was to determine the factors predictive of malignancy in thyroid nodules when cytological assessment is restricted to euthyroid patients living in an area without endemic goiter who undergo routine diagnostic lobectomy once the FNA raises the suspicion of a follicular neoplasm.
  • Histology demonstrated thyroid carcinomas in 57 patients (31 follicular carcinomas, 11 Hurthle cell carcinomas, 11 papillary carcinomas, 1 medullary thyroid carcinoma, 1 poorly differentiated thyroid cancer, 1 lymphoma, and 1 metastatic renal carcinoma).
  • Benign tumors were found in 144 patients with follicular adenomas (n = 76), Hurthle cell adenomas (n = 33), multinodular goiter (n = 13), adenomatoid nodules (n = 15), colloid nodules (n = 4), and thyroiditis (n = 3).
  • About 17/46 nodules over 40 mm in diameter were carcinomas, compared with only 35/140 in nodules under 40 mm (p < 0.01, chi2 test).
  • CONCLUSION: One in four patients with cytological features of a follicular neoplasm has a thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cohort Studies. Diagnosis, Differential. Female. Humans. Incidence. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Risk Factors. Thyroidectomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976164.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • Squamous carcinoma showed negative CK7/20 immunoexpression.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


89. Chow TL, Choi CY, Lam SH: Disease control of differentiated thyroid carcinomas by hemithyroidectomy. Singapore Med J; 2010 Apr;51(4):311-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease control of differentiated thyroid carcinomas by hemithyroidectomy.
  • INTRODUCTION: Most differentiated thyroid carcinomas (DTC) are treated by total thyroidectomy in Hong Kong.
  • Patients with pathologically proven differentiated thyroid carcinoma were stratified into risk groups according to the patients' age, tumour size, extrathyroid spread and distant metastasis.
  • Central compartment lymph node dissection was also carried out if the diagnosis was confirmed preoperatively.
  • RESULTS: A total of 236 patients with the diagnosis of DTC underwent a thyroidectomy at our institution during a 24-year period.
  • The histopathologic diagnoses were papillary carcinoma (69 cases; 74.2 percent), follicular carcinoma (20 cases; 21.5 percent) and Hurthle cell carcinoma (four cases; 4.3 percent).
  • [MeSH-major] Carcinoma / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505909.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


90. Di Cristofaro J, Silvy M, Lanteaume A, Marcy M, Carayon P, De Micco C: Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genes. Endocr Relat Cancer; 2006 Jun;13(2):485-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, little is known about the fate of TPO in thyroid carcinoma.
  • We performed a qualitative PCR (Q-PCR) analysis to measure the expression of variants of tpo mRNA in 13 normal tissue samples, 30 benign tumors (BT), 21 follicular carcinomas (FC), 20 classical papillary carcinomas (PCc), 12 follicular variants of papillary carcinomas (PCfv) and nine oncocytic carcinomas (OC).
  • Results of Q-PCR were closely correlated with those of ICC (P < 0.0001; R = 0.59) and showed that overall tpo expression was lower in all carcinomas than in normal and BT (P < 0.05).
  • The ratio tpo2 or tpo3 to tpo1 was inversed in follicular tumors.
  • These results confirmed the decrease of TPO expression in 97% of thyroid carcinomas regardless of histological type and the overexpression of shorter splice variants in follicular tumors.
  • [MeSH-major] Carcinoma / enzymology. Gene Expression Regulation, Neoplastic. Genes, Neoplasm / genetics. Iodide Peroxidase / genetics. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728576.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; EC 1.11.1.8 / Iodide Peroxidase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


91. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of oncocytic carcinoma of the endometrium.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Components of the carcinoma were focally observed in situ.
  • Immunostaining revealed endometrial oncocytic carcinoma.
  • Distinguishing between primary uterine neoplasm and carcinoma caused by metastasis of breast cancer appears important.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


92. Fonseca E, Soares P, Cardoso-Oliveira M, Sobrinho-Simões M: Diagnostic criteria in well-differentiated thyroid carcinomas. Endocr Pathol; 2006;17(2):109-17
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic criteria in well-differentiated thyroid carcinomas.
  • The criteria used for the differential diagnosis of well-differentiated thyroid tumors derived from follicular cells are reviewed taking into account the architectural characteristics together with the immunohistochemical and molecular features.
  • The review is focused on follicular carcinoma, papillary carcinoma, follicular variant of papillary carcinoma, and oncocytic (Hürthle cell) tumors, as well as on the recently described borderline lesions: follicular and well-differentiated tumors of uncertain malignant potential, and well-differentiated carcinoma, not otherwise specified.
  • [MeSH-major] Carcinoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / classification. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / diagnosis. Adenoma / classification. Adenoma / diagnosis. Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17159243.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


93. D'Antonio A, Caleo A, Caleo O, Addesso M, Boscaino A: Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma. Hepatobiliary Pancreat Dis Int; 2010 Oct;9(5):550-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma.
  • BACKGROUND: Renal metastases of hepatocellular carcinoma (HCC) are very rare.
  • RESULTS: Histologically, the tumor was composed mainly of epithelioid cells with homogeneous acidophilic cytoplasm resembling oncocytoma or primary renal carcinoma with oncocytic features.
  • A correct diagnosis was made on the basis of positive immunostaining for hepatocyte paraffin 1.
  • Since HCC may histologically resemble primary renal tumors such as oncocytoma, pathologists must be aware of this possibility above all in patients referred for liver transplantation and treated with immunosuppressant drugs.
  • Immunohistochemistry is particularly helpful to establish a precise diagnosis in cases of doubt.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Diagnosis, Differential. Fatal Outcome. Female. Humans. Liver Transplantation / pathology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943467.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Oncocytoma, renal
  •  go-up   go-down


94. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G: RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab; 2006 Jun;91(6):2414-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
  • CONTEXT: RET/papillary thyroid cancer (PTC) is a marker for papillary thyroid carcinoma, but its specificity has been questioned because of the disputed identification of RET/PTC in Hashimoto's thyroiditis (HT), oncocytic tumors, and other thyroid lesions.
  • OBJECTIVE: The objective of this study was to determine 1) whether RET/PTC occurs in nonneoplastic follicular cells of HT, and 2) its recombination rate in thyroid tumors.
  • DESIGN/PATIENTS: Forty-three samples from 31 cases of HT were examined using interphase fluorescence in situ hybridization (FISH) with RET probes spanning the breakpoint region; real-time RT-PCR to quantify RET/PTC1, RET/PTC3, and c-RET transcripts; and RT-PCR after laser capture microdissection to enrich samples for follicular cells.
  • The results were compared with those similarly obtained in 34 papillary carcinomas, eight thyroid oncocytic tumors, and 21 normal thyroids.
  • Sixty-eight percent (15 of 22) of HT were positive by FISH; in all thyroiditis, signals were localized to rare nonneoplastic follicular cells; low-level RET/PTC was identified in 17% (five of 29) of thyroiditis cases by real-time RT-PCR and in an additional six of 11 real-time negative cases after increasing sensitivity with laser capture microdissection.
  • Low RET/PTC1 levels were detected in 26% (nine of 34) of papillary carcinomas with an expression pattern and proportion of FISH-positive cells similar to those of the thyroiditis.
  • Forty-seven percent (16 of 34) of papillary carcinomas and one oncocytic carcinoma expressed high RET/PTC1 mRNA levels.
  • CONCLUSIONS: Low-level RET/PTC recombination occurs in nonneoplastic follicular cells in HT and in a subset of papillary thyroid carcinomas.
  • RET/PTC expression variability should be taken into account for the molecular diagnosis of thyroid lesions.
  • [MeSH-major] Carcinoma, Papillary / genetics. Gene Rearrangement. Hashimoto Disease / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. Recombination, Genetic. Thyroid Gland / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Line. Humans. In Situ Hybridization, Fluorescence. Interphase. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2006 Jun;91(6):2040-2 [16757533.001]
  • (PMID = 16595592.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human
  •  go-up   go-down


95. Eiss D, Larousserie F, Mejean A, Ghouadni M, Merran S, Correas JM, Hélénon O: [Renal oncocytoma: CT diagnostic criteria revisited]. J Radiol; 2005 Dec;86(12 Pt 1):1773-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal oncocytoma: CT diagnostic criteria revisited].
  • PURPOSE: To redefine and evaluate the computed tomographic criteria for the diagnosis of renal oncocytoma (RO) for which renal sparing surgery should be preferred.
  • A double blinded comparative study was made of 60 renal tumors (containing adenocarcinomas and oncocytomas) larger than 3 cm in diameter in order to evaluate the redefined CT diagnostic criteria.
  • The use of our CT diagnostic criteria gave a statistically significant (p < 0.05) Kappa index of inter-observer concordance of 0.71 and a specificity of 96% for the diagnosis of RO.
  • CONCLUSION: Our redefined computed tomographic criteria for the diagnosis of renal oncocytoma, eventually associated with renal biopsy, should increase the indications for renal sparing surgery for RO larger than 3 cm in diameter.
  • [MeSH-major] Adenoma, Oxyphilic / radiography. Kidney Diseases / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333226.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


96. Schwarz S, Stiegler C, Zenk J, Iro H, Agaimy A: [Salivary gland mucoepidermoid carcinoma: unusual variants with detection of the t(11,19)(q21;p13) translocation]. Pathologe; 2009 Nov;30(6):472-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salivary gland mucoepidermoid carcinoma: unusual variants with detection of the t(11,19)(q21;p13) translocation].
  • Mucoepidermoid carcinoma (MEC) represents the most common malignant salivary gland tumour.
  • Based on the proportion of their constituent cell types, MECs may display a wide morphological spectrum, thereby mimicking diverse types of other primary salivary gland carcinomas.
  • The correct diagnosis relies on demonstration of classical MEC features, assisted by histochemical and immunohistochemical stains in equivocal cases.
  • The differential diagnosis includes squamous cell carcinoma, clear cell carcinoma and oncocytic neoplasms, as well as highly malignant adenocarcinomas which cannot be further classified.
  • [MeSH-major] Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / pathology. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Parotid Neoplasms / genetics. Parotid Neoplasms / pathology. Submandibular Gland Neoplasms / genetics. Submandibular Gland Neoplasms / pathology. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Female. Humans. Male. Neoplasm Staging. Parotid Gland / pathology. Submandibular Gland / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820938.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Lefèvre M, Couturier J, Sibony M, Bazille C, Boyer K, Callard P, Vieillefond A, Allory Y: Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol; 2005 Dec;29(12):1576-81
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
  • We report a series of 10 oncocytic renal papillary tumors, with the aim of determining their clinicopathologic features.
  • They consisted of thin, nonfibrotic papillae lined by a single layer of oncocytic cells, with finely granular eosinophilic cytoplasm and round regular nucleus exhibiting central nucleolus (Fuhrman grade II, except for one grade III).
  • All tumors were immunoreactive for alpha-methylacyl-coenzyme A racemase, vimentin, and CD10; 4 expressed renal cell carcinoma antigen and 3 cytokeratin 7.
  • Papillary architecture, necrosis, and immunohistochemical profiles argued against the diagnosis of oncocytoma and suggested our cases to be part of the papillary renal cell carcinoma group.
  • However, the cases were atypical for type 1 papillary carcinoma (due to oncocytic cells and absence of trisomy 17) and for type 2 (due to a good outcome).
  • These results suggest that adult papillary renal tumors with oncocytic cells might be a distinct variant in the papillary renal cell carcinoma group.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / pathology. Cytogenetics. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327429.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW: Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg; 2008 May;32(5):722-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
  • BACKGROUND: The BRAF V600E mutation is the most prevalent genetic aberration in papillary thyroid carcinomas (PTCs), and it is found exclusively in RET/PTC-negative tumors.
  • In oncocytic (Hürthle cell, oxyphilic) thyroid tumors, the presence of RET/PTC rearrangements is associated with either the conventional papillary histotype or the "solid" Hürthle cell tumors, whereas all predominantly follicular oncocytic carcinomas do not harbor RET/PTC chimeras.
  • Although 12% of tumors of the follicular variant of PTC carry BRAF mutations, none of the few oncocytic follicular thyroid adenomas (oncoAd) or carcinomas (oncoFTC) published worldwide tested positive.
  • An aspired molecular-based classification of oncocytic thyroid tumors is in need of additional evidence on BRAF mutations in the follicular histotype.
  • METHODS: A series of 44 oncocytic thyroid tumors with well-documented clinicopathological data was subjected to BRAF mutation analysis (complete exon 15) by automated sequencing.
  • RESULTS: The series of oncocytic thyroid tumors consisted of 21 adenomas (oncoAds: 17 females, 4 males; mean age, 54.5 years; range, 27-80 years), 20 follicular carcinomas (oncoFTCs: 14 females, 6 males; mean age, 61.4 years; range, 39-80 years), and 3 "classic" papillary carcinomas (oncoPTCs: 3 females; mean age, 58.1 years; range, 46-70 years; 3x T2 tumors).
  • The follicular variants of oncocytic cancers are divided into 11x T2, 5x T3, and 4x T4 tumor stages (International Union Against Cancer [UICC] TNM 5th edition).
  • CONCLUSIONS: Our results add to the evidence that, in contrast to follicular variants of oncoPTCs, predominantly follicular oncocytic thyroid tumors harbor neither RET/PTC rearrangements nor BRAF mutations.
  • Furthermore, the findings support the concept that oncocytic neoplasms of the thyroid gland are oncocytic counterparts of the respective histotype (adenoma, FTC, PTC, or poorly differentiated thyroid carcinoma) rather than a separate tumor entity.
  • Molecular characterization of oncocytic thyroid malignancies for RET/PTC or BRAF genetic alterations may help with (preoperative) classification and prognostic evaluation of these tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / genetics. Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235983.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


99. Nix PA, Nicolaides A, Coatesworth AP: Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer. Int J Clin Pract; 2006 Jan;60(1):80-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, the rare forms of thyroid cancer which comprise medullary thyroid cancer arising from parafollicluar C cells, Hurthle cell carcinoma, anaplastic carcinoma, thyroid lymphoma and squamous cell carcinoma are typically associated with a poorer survival rate.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Humans. Lymphoma / diagnosis. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409432.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


100. Chamnanrabiabkij E, Welch A, Jayapaul MK, Perros P: Detection of Hurthle cell carcinoma using sestamibi. Thyroid; 2008 May;18(5):575-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Hurthle cell carcinoma using sestamibi.
  • [MeSH-major] Adenoma, Oxyphilic / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroid Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044993.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down






Advertisement